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ABSTRACT
 Lung metastasis remains a leading cause of death in breast cancer patients. This 
study established an innovative 3D ex vivo pulmonary metastasis assay (PuMA) to test 
the hypothesis that the lung microenvironment promotes metastatic behaviour of whole 
population and stem-like ALDHhiCD44+ breast cancer cells. Following in vivo delivery of 
breast cancer cells to mice, lungs were excised, maintained in culture and imaged to 
observe breast cancer growth over time. We observed metastatic progression of breast 
cancer cells in the PuMA, most notably of ALDHhiCD44+ cells which progressed rapidly 
from single cells to multicellular colonies over 21 days relative to their ALDHloCD44- 
counterparts (p≤0.05). Although soluble lung-derived bFGF induced breast cancer cell 
proliferation in vitro, blocking bFGF in the PuMA showed only a trend towards inhibition 
of breast cancer cell growth. This model system will be valuable for elucidating the 
interaction between breast cancer cells and the lung during metastatic progression. 
Keywords: Breast cancer, metastasis, organ-specific tropism, pulmonary metastasis 
assay (PuMA), cancer stem cell, aldehyde dehydrogenase (ALDH), CD44, basic 
fibroblast growth factor (bFGF).  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1. INTRODUCTION
Despite earlier screening and ongoing research in the areas of cancer treatment 
and prevention, cancer remains the leading cause of death in developed countries 
worldwide. Interestingly, cancer prevalence is also increasing in developing areas of 
the world as a result of population growth and aging as well as the adoption of risk-
factor associated lifestyles (smoking, inactivity, “westernized” diets) [1, 2].  
 Breast cancer is the second most common cancer in the world and ranks number 
one in terms of most frequent cancer diagnoses amongst women and the second 
leading cause of cancer related deaths in North America [1-4]. Over the past 25 years 
we have seen a drastic increase in overall 5-year survival rates for patients with breast 
cancer, largely due to improvements in treatment and the widespread use of 
mammography [5]. Breast cancer caught early on results in 5-year survival rates of 
98.6% and 84.4% for localized and regional breast cancers, respectively [6]. 
However, survival rate significantly declines to less than 25% in women diagnosed 
with late-stage metastatic spread [6, 7]. Therefore, the majority of deaths associated 
with breast cancer are not due to the burden of the primary tumour, but rather the later 
stages following metastatic spread, especially towards the lungs [8, 9].  
 The focus of this thesis is to investigate the importance of the native lung 
microenvironment on the behaviour of both whole population and stem-like breast 
cancer cells using an innovative 3D animal model, so we can better understand which 
aspects of the lung make it a permissible environment for breast cancer to grow and 
progress.
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2. LITERATURE REVIEW
2.1. Cancer
Cancer is a complex set of diseases characterized by the failure of cellular 
growth regulation. Loss in regulation most often occurs by means of genetic 
disruption, eventually resulting in loss of homeostasis and subsequent aberrant 
growth and unlimited proliferative capacity. Fundamentally, characteristics acquired 
during cancer growth and progression include self-sufficiency in growth signalling, 
insensitivity to anti-growth signals, acquisition of limitless replicative capacity, 
ability to promote and sustain angiogenesis, evasion of apoptosis and tissue invasion 
and metastasis [10, 11].  
 Malignant transformation of normal cells can often be linked to disruptions in 
two different categories of genes: oncogenes and tumour suppressor genes. 
Oncogenes are those that promote cell growth and reproduction and are tumour-
promoting when over stimulated. When constitutively activated, oncogenes cause 
cells destined for apoptosis or cell death to survive and continue to proliferate [12]. In 
contrast, tumour suppressor genes are those that inhibit cell division and survival and 
promote apoptosis and cell cycle arrest [13]. Typically, mutations or epigenetic 
changes in several genes are needed to transform a healthy cell into a malignant one 
[14, 15].  
 Cancers are typically classified according to the cell type in which they 
resemble and therefore most likely derive from. For example, carcinomas are cancers 
derived from epithelial cells, sarcomas from connective tissue, lymphoma or 
leukaemia from hematopoietic origin, germ-line tumours from germ-line cells and 
blastomas from embryonic cells [16]. Benign tumours are those which remain 
contained within the tissue of origin and are not usually life-threatening. In contrast, 
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malignant tumours are life threatening and are able to invade surrounding tissues and 
move to distant areas of the body separate from the primary tumour [12].
2.2. Breast Cancer
The principle structure of the breast is the mammary gland. The mammary 
gland is composed of alveoli lined with milk-producing cuboidal epithelia surrounded 
by a layer of myoepithelia. Many alveoli join together to form groups called lobules, 
each having a lactiferous duct responsible for draining to the nipple, composed of 
ductal epithelia surrounded by myoepithelia [17, 18]. Breast cancer is neoplastic 
formation originating from breast tissue, most commonly from the ducts that carry 
milk or the lobules that supply them. The susceptibility of these structures to benign 
and malignant transformations are in part a consequence of cycling hormonal 
stimulation throughout life leading to increased cell turnover and accumulation of 
genetic defects [19, 20].  
 Cancer originating from the milk ducts and lobules are referred to as ductal 
carcinoma or lobular carcinoma, respectively [21]. Ductal carcinoma represents the 
most commonly diagnosed breast tumour, accounting for approximately 75% of 
breast cancer cases [22, 23]. Breast cancer can often be classified according to 
different schemas. Histopathological analysis is commonly used when determining 
the class of breast cancer. Tumours confined within the ducts or lobules that have not 
spread beyond their borders are referred to as either ductal carcinoma in situ (DCIS) 
or lobular carcinoma in situ (LCIS). Both DCIS and LCIS are non-invasive in nature 
and lack invasion into surrounding tissues [24, 25]. Therefore, when breast cancer 
remains in situ, traditional treatments are highly effective if required [26]. Prognosis 
worsens for patients with invasive ductal or lobular carcinoma; characterized by 
tumour that has infiltrated surrounding tissues [27]. Invasive disease often leads to 
further cancer dissemination throughout the body, leading to distant metastatic 
disease. Many of the traditional methods for treating breast cancer often fail once the 
cancer has reached the metastatic setting [28]. Therefore, the majority of deaths 
associated with breast cancer are attributed to cancer that has spread from the initial 
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region of the breast to distant organs [8, 9], necessitating a deeper understanding of 
this complex metastatic process.
2.3. Breast Cancer Subtypes
In addition to histopathological classification, breast cancer can also be 
categorized according to molecular subtype [22]. Genomic profiling and 
immunohistochemical markers have revealed the presence of specific molecular 
subtypes with predictable clinical behaviours. The Cancer Genome Atlas (TCGA) 
classifies breast cancer subtypes into one of four specific groups: luminal A, luminal 
B, HER2-enriched or basal-like (triple negative; TN) [29-31]. Although a complex 
molecular and genetic profile is needed to determine exact subtype, most subtypes 
can be roughly defined by hormone receptor status (estrogen and progesterone), 
HER2/neu status (a member of the epidermal growth factor receptor family) and 
proliferation rate [32, 33]. Luminal A tumours resemble the inner linings of mammary 
ducts and tend to be ER+/PR+ and HER2-. Since these tumours are often ER+, they 
respond well to hormone therapy and often have favourable  prognoses and survival 
rates  associated  with  them [34,  35].  Luminal  B  tumours  also  resemble  the  inner 
linings of mammary ducts and tend to be ER+/PR+ but are highly positive for the 
proliferative marker Ki-67 and/or HER2+. Women diagnosed with these tumours also 
tend  to  have  fairly  high  survival  rates,  but  not  as  high  as  those  with  luminal  A 
tumours [35, 36]. HER2-enriched tumours are most commonly ER-/PR- and HER2+, 
although a small percentage of this subtype are HER2-. These tumours often have a 
poorer prognosis and are prone to metastasis and frequent recurrence [31, 32, 37]. 
HER2+  tumours  can  however  be  treated  with  the  targeted  therapy  Herceptin 
(trastuzumab),  which  targets  the  HER2  surface  receptor  on  breast  cancer  cells, 
slowing growth and progression [38]. Basal-like or TN breast tumours share features 
with the outer lining of mammary ducts and are defined as ER-/PR- and HER2-. Most 
TN breast cancers are highly aggressive and have a poor prognosis and relatively low 
5-year survival rates [32, 39, 40]. 
!5
Traditionally, molecular subtype classification has been involved with aiding 
clinical treatment decisions for patients, particularly in terms of targeted therapies. 
However, breast tumour populations are often heterogeneous in nature and therefore 
are comprised of cells with varying molecular subtypes. Therefore, molecular subtype 
classification should not be used exclusively as a means of treatment consideration, 
especially as we continue to appreciate the vast heterogeneity that exists within solid 
breast tumours [41]. !
2.4. Metastasis
Metastasis is a complex process by which a series of cellular events are 
ultimately responsible for tissue invasion and distant tumour establishment [42]. The 
metastatic process consists of a series of coordinated steps in a prototypical cascade. 
Over time, rare subsets of tumour cells acquire a more invasive phenotype and break 
off from the primary tumour. Invasive tumour cells attach to basement membranes 
and release extracellular matrix (ECM) degrading enzymes and factors, which 
facilitate infiltration into surrounding tissues and entry into the circulation or 
lymphatics [43]. As primary tumours grow and develop, they require a supply of 
oxygen to support metabolic needs, and therefore promote angiogenesis or the 
recruitment of new blood vessels. Angiogenesis and the proximity of a blood supply 
to the tumour also provide a route by which tumour cells can invade the vasculature 
and spread [28, 44]. Once in the circulation, tumour cells need to survive, which often 
represents a rate limiting step for metastasis. Successful circulating tumour cells 
(CTC) remain in the circulation until they extravasate into a new tissue where they 
ultimately initiate and establish a secondary tumour, distant from the primary tumour 
[28, 45, 46] (Figure 1). Metastasis is an inherently inefficient process as only a small 
subset of invading tumour cells are able to successfully establish secondary tumours 
and survive within the tissue [47]. Although this process is relatively inefficient, it 
still remains one of the most important issues regarding cancer related deaths. Many 
conventional  anti-cancer  therapies  such  as  surgery,  radiotherapy,  and  hormone 
therapy are fairly successful when treating cancers detected and diagnosed prior to  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Figure 1. The metastatic cascade. Metastasis is a complex process by which tumour 
cells spread to distant sites throughout the body. This occurs by a series of coordinated 
cellular events: (A) Development of a primary tumour, (B) a subset of primary tumour 
cells invade and enter surrounding tissue and vasculature, (C) tumour cells disseminate 
within the blood and/or lymphatics, (D) tumour cells attach to vessel walls and 
extravasate into a secondary tissue, (E) tumour cells establish a secondary tumour distant 
from the primary tumour site. The final step represents a metastatic lesion. 
A. Primary tumour
B. Invasion
C. Dissemination
D. Extravasation
E. Secondary tumour 
establishment
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distant  metastasis.  However,  most  current  therapies ultimately fail  with respect  to 
metastatic  tumours,  for  reasons still  poorly understood [28].  Therefore,  metastatic 
progression illustrates a fundamental event for understanding during the progression 
of cancer. 
2.5. Organ-specific Tropism
Although most cancers have the potential to spread to multiple organs, they 
usually prefer certain sites in relation to others. The preference of particular cancers 
to metastasize to specific organs is termed “organ tropism” and it has been well 
established that breast cancer exhibits this phenomenon [28, 29, 48, 49]. Clinically, 
the most common sites for breast cancer to spread to are the lung, bone, liver, brain 
and lymph nodes (LN). Metastasis to the lung is of particular interest due to its poor 
prognosis and lethality in breast cancer patients [29].  
Multiple theories have been developed to explain the process of organ-specific 
tropism, including Stephen Paget’s seminal “seed and soil” hypothesis in 1889, and 
Ewing’s mechanical arrest theory [50]. Paget’s original theory suggested that organ-
specific patterns of metastasis are the result of favourable interactions between 
tumour cells (the ‘seed’) and their respective organ microenvironment in the 
secondary site (the ‘soil’) [51]. Paget’s theory therefore predicts that certain cancer 
cells can survive and proliferate only in secondary sites that produce appropriate 
factors to sustain growth and survival. In contrast, Ewing’s theory some forty years 
later postulates that metastatic dissemination is strictly the result of mechanical 
factors caused by the nature of the vascular system, meaning that cells are 
mechanically arrested in the first capillary beds they encounter [52]. It is likely that 
these two theories operate in concert rather than alone to produce and maintain 
secondary tumour growth, as evidence has shown both theories hold true. That is, 
breast cancer cells invade the local vasculature, are taken to the heart via the venous 
circulation and subsequently delivered to the lungs where they mechanically arrest in 
the first capillary beds they encounter. While there, successive initiation, growth and 
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maintenance of secondary tumours within the lung is influenced, at least in part, by 
specific lung-derived factors [53].
2.6. Importance of Molecular Subtype
It is widely believed that as a result of genomic instability within tumour 
populations, large-scale cellular heterogeneity develops in cancer. As a consequence, 
tumour cell variants with augmented metastatic capabilities arise through selective 
pressures [54-56]. Several studies have demonstrated specific genetic signatures or 
molecular characteristics associated with organ-specific patterns of metastasis in 
breast cancer [53]. As mentioned previously, breast cancers are often classified into 
one of four major molecular subtypes (luminal A/B, HER2-enriched or TN) based on 
genetic and immunohistochemical markers [29, 30]. One particular study by 
Kennecke and colleagues examined the metastatic dissemination patterns for patients 
with different breast cancer subtypes. Using 15-year cumulative incidence rates 
according to metastatic site, they concluded that certain subtypes were associated 
with particular patterns of metastatic spread. In particular, they found more aggressive 
subtypes (HER2+ and TN) had a propensity for the lungs whereas less aggressive 
subtypes preferred the bone as a metastatic site. Importantly, this disparity supports 
the idea that certain molecular characteristics associated with breast cancer cells may 
be involved in promoting organ-specific patterns of spread [29, 53].  
2.7. Breast Cancer Cell Gene Signature Can Influence Organ Tropism 
In addition to specific patterns of metastatic spread based on molecular 
subtype, work done by Joan Massagué’s group has also supported the notion that 
molecular characteristics are in part responsible for organ-tropism. Their 
experimental studies set out to determine a specific gene signature associated with 
patterns of lung-specific metastasis in breast cancer. Using a mouse model of lung 
metastasis, their group was able to successfully generate a lung-seeking variant of the 
aggressive TN human breast cancer cell line MDA-MB-231 through multiple rounds 
of in vivo selection [56]. Following transcriptome analysis of both parental and lung-
seeking variants, their work revealed a gene signature associated with lung-specific 
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metastasis distinct from a previously identified bone-specific signature. Interestingly, 
many genes identified had not been previously linked to metastasis. Genes that did 
correlate with metastasis were comprised of extracellular and receptor proteins 
including a HER receptor ligand (epiregulin; EREG), adhesion receptors (ROBO1), 
specific chemokines (CXCL1), secreted proteases (MMP1), and transcriptional 
regulator proteins (ID1, ID3) [45, 57, 58]. These important findings suggest an 
intimate relationship between cancer cells, their genetic signature and specific organ 
microenvironments most permissive to their growth and survival. However, it 
remains relatively unclear as to when and why subsets of tumour cells acquire these 
gene signatures during the progression of cancer. 
2.8. Stem-like Breast Cancer Cells 
 Recent studies have described a unique subpopulation of cancer cells within 
solid tumours termed “cancer stem cells” (CSC) [59,  60].  These cells  represent  a 
small  subset  of  cells  within  the  tumour  characterized  by  stem-like  properties 
including self-renewal and multi-lineage differentiation [61].  The cancer stem cell 
model suggests that CSCs represent a distinct population of tumour cells ultimately 
responsible for tumour initiation, metastatic spread and therapy resistance [60]. The 
first  evidence to support  this  hypothesis  was provided in 1994 by John Dick and 
colleagues,  who  demonstrated  that  human  acute  myeloid  leukemia  (AML)  was 
organized  as  a  hierarchy  that  originates  from  a  primitive  leukemia-initiating 
hematopoietic cell [62, 63]. In breast cancer, tumour-initiating cells or CSCs have 
been isolated from patient tumours and various breast cancer cell lines based on a 
CD44+CD24-  phenotype  and/or  high  aldehyde  dehydrogenase  (ALDH)  activity 
[64-67].  CD44  is  a  cell  surface  glycoprotein  with  well-defined  roles  in  cell-cell 
interactions, cell adhesion, migration and metastasis [68]. The ALDH superfamily of 
intracellular enzymes is involved in the detoxification of aldehydes [67, 69, 70] with 
ALDH1A1  and  ALDH3A1  isoforms  having  defined  roles  in  normal  stem  cell 
function and self-protection [71]. Interestingly, high expression of ALDH1 has been 
associated with a poorer prognosis in breast cancer patients as well as an increased 
risk of metastatic progression [72, 73]. Previous work done by Alysha Croker in our 
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lab  demonstrated  that  high  ALDH  activity  in  addition  to  CSC  surface  marker 
expression (CD44+CD24-) selects for a highly enriched population of stem-like breast 
cancer cells with enhanced metastatic properties and therapy resistance [67]. In this 
study,  ALDHhiCD44+ breast  cancer  cells  isolated  from MDA-MB-468 and  MDA-
MB-231  breast  cancer  cell  lines  demonstrated  enhanced  cell  growth,  colony 
formation, migration, and invasion in vitro as well as enhanced tumourigenicity and 
metastasis  in  vivo  [67].  This  data  demonstrates  the  functional  importance  of 
ALDHhiCD44+ breast cancer cells in promoting many of the events that accompany 
metastatic progression.
2.9. The “Soil”: Organ Microenvironments
It is becoming increasingly clear that specific organ microenvironments have a 
profound influence on the biology of tumour growth and survival. The end result of 
the metastatic cascade (development of clinically relevant macrometastases) depends 
greatly on the interactions between metastatic cells and host homeostatic mechanisms 
[48, 57]. Previous studies have conclusively demonstrated in animal models that 
tumour cells are able to reach the microvasculature of many organs but sustained 
growth, survival and progression only occurred within specific organs [74, 75]. These 
studies support the role of certain organ microenvironments in promoting and 
sustaining metastases within a secondary environment. Once tumour cells reach 
distant organs, they must proliferate to establish a successful secondary tumour. To 
accomplish this, tumour cells can usurp physiological growth factors produced by the 
microenvironment. In addition, the organ microenvironment can also influence how 
metastases respond to common means of clinical intervention, including 
chemotherapy and radiation [76]. For example, previous studies by Wilmanns et al. 
have observed that murine fibrosarcomas or colon carcinomas grown subcutaneously 
in syngeneic mice were sensitive to systemic administration of doxorubicin, whereas 
lung or liver metastases were not [59]. Therefore, new therapeutic approaches for 
metastasis should be targeted not only against tumour cells but also against host 
factors favourable to tumour metastasis, growth, and survival.
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2.10. Soluble Lung Microenvironment
Previous work done in our lab by Jenny Chu has led to the development and 
establishment of a comprehensive ex vivo murine model for studying the influence of 
organ-derived  soluble  factors  on  breast  cancer  cell  metastatic  behaviour.  Organs 
representing  common clinical  sites  of  breast  cancer  metastasis  (lung,  bone,  liver, 
brain, LN) were harvested from female nude mice and cultured for the purposes of 
generating organ conditioned media (CM) [52]. Using this model, Chu demonstrated 
that  different  human  breast  cancer  cell  lines  show  specific  chemotactic  and 
proliferative  behaviours  in  response  to  various  organ-CM,  reflective  of  their 
metastatic behaviours in vivo [50, 53]. Specifically, the most aggressive of the cell 
lines,  MDA-MB-231,  showed  increased  migration  patterns  towards  bone,  lymph 
node,  and  lung-CM.  The  second  most  aggressive  cell  line,  SUM159,  displayed 
enhanced migration towards the bone, brain, LN, and while the two least aggressive 
cells lines (SUM149 and MDA-MB-468) demonstrated increased migration to lung-
CM only. More specifically, Chu’s work has also shown that stem-like ALDHhiCD44+ 
breast  cancer  cells  exhibit  preferential  migration  towards  lung-CM over  all  other 
organ conditions, complementing Croker’s previous work demonstrating that these 
cells  preferentially  migrate  to  the  lung  in  vivo  [52,  67].  In  addition  to  increased 
migratory patterns,  MDA-MB-231 and MDA-MB-468 cell  lines demonstrated cell 
line specific patterns of proliferation in response to organ-CM. MDA-MB-231 cells 
showed  increased  proliferation  in  the  presence  of  liver  and  lung-CM and  MDA-
MB-468 cells showed increased proliferation in the presence of lung-CM [52]. These 
results indicate the potential of the lung microenvironment in promoting metastatic 
progression of breast cancer cells as demonstrated by enhanced patterns of migration 
and proliferation in response to lung-CM. 
Protein array analysis of lung-CM identified numerous soluble factors within 
the lung microenvironment possibly contributing to breast cancer metastasis. Many of 
these factors have implications during metastasis, migration, growth and adhesion. 
One protein identified and of particular interest to our group is basic fibroblast growth 
factor (bFGF or FGF-2) [52].  bFGF is one of 22 mitogenic members of the FGF 
family, involved in wound healing, tissue repair, and embryonic development [77-79]. 
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Both low molecular weight (LMW) and high molecular weight (HMW) isoforms of 
bFGF have been characterized, representing alternative translation products from a 
single mRNA. The 18 kDa LMW isoform is primarily localized to the cytoplasm and 
is  the  secreted  form,  whereas  HMW  (21-23  kDa)  bFGF  contains  a  nuclear 
localization sequence (NLS)-like domain and is targeted to the nucleus [80-83]. Most 
stimulatory effects induced by bFGF occur through the secreted LMW isoform and 
canonically  signal  through  the  specific  transmembrane  fibroblast  growth  factor 
receptors (FGFR).  There are four tyrosine kinase FGF receptors (FGFR1-4),  with 
bFGF preferentially binding to FGFR1 or FGFR2 with higher affinity than FGFR3/4. 
Non-canonically,  bFGF  also  interacts  and  signals  through  alternative  receptors, 
including CD44 and vβ3 [77, 83].
bFGF has been implicated in cancer previously, as a proliferation-inducing 
signal and during angiogenesis [81, 84, 85]. bFGF is of particular interest to us due to 
its  potent  mitogenic  capacity,  as  well  as  its  ability  to  signal  through  the  CD44 
receptor, which is present on stem-like breast cancer cells [52, 67, 70]. However, its 
role in the metastatic progression of breast cancer within the lung has not previously 
been  explored.  This  coupled  with  the  fact  that  this  protein  has  been  previously 
identified in our lab as a soluble factor present in lung-CM has led our interest as to 
the influence of bFGF during metastatic progression of breast cancer in the lung.
2.11. Insoluble Lung Microenvironment
The role of the lung microenvironment during cancer initiation and progression 
is for a large part, poorly understood. The lung is composed of over 60 different cell 
types  involved  in  various  functions  including  sensory,  mechanical,  secretory  and 
transport [86]. While the soluble microenvironment is much more intuitive to think of 
as a contributor to cancer progression, we cannot disregard the influence the insoluble 
microenvironment may play in this dynamic process. In the lung specifically, about 
15% of alveolar tissue and 50% of non-alveolar tissue is noncellular, or ECM [87]. 
The ECM is  composed of  a  myriad of  structural  proteins  including collagen and 
elastin,  specialized  proteins  such  as  fibronectin  and  laminin,  as  well  as  high-
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molecular weight proteoglycans, which function to support surrounding parenchymal 
cells [88-90]. 
Many types of epithelial and endothelial cells are dependent upon adhesion to 
the ECM for their continued survival and often undergo apoptosis when this adhesion 
is disrupted [91]. Although cancer cells are characterized by their unique ability to 
progress and grow in the absence of ECM adhesion, solid tumours often exist in a 
dynamic  relationship  between  anchorage-dependence  and  independence  [92].  One 
potential implication of this is that tumour cells bound to the ECM may be relatively 
protected from chemotherapy compared to non-adhered cells. Therefore, the insoluble 
lung microenvironment in addition to soluble microenvironmental factors may have a 
profound impact on the growth and therapy response patterns of cancer cells in the 
lung.
2.12. Techniques for Studying Metastasis in vivo
Traditionally,  most  metastasis-related  research  revolves  around  endpoint 
analysis, e.g. after a detectable tumour has formed within a secondary site. While this 
research sheds important light in terms of how and where tumours grow once they 
metastasize, there often exists a lack of mechanistic knowledge as to how these cells 
actually escape the primary tumour, invade and exit the vasculature, and ultimately 
establish a secondary colony from the single cell stage. There exists a biological black 
box during the metastatic progression from single tumour cells to the formation of 
gross metastatic lesions [93]. Several attempts have been made to understand these 
important  initial  steps  of  metastatic  progression  by  imaging  the  early  stages  of 
metastasis in vivo. Many of these modalities include techniques that mirror methods 
for human imaging, including computer tomography (CT), micro-positron emission 
tomography  (PET),  and  magnetic  resonance  imaging  (MRI)  [94,  95].  However, 
techniques also exist  that  lack a human correlate such as optical  imaging (OI) of 
bioluminescence  (BLI)  or  fluorescence  (intravital  video  microscopy;  IVM).  OI 
represents a unique tool for whole body imaging in small animals. For example, BLI-
based imaging has been used to monitor the development and progression of bone 
metastases in living animals  with a  high degree of  sensitivity [96,  97].  Similarly, 
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IVM-based  cellular  imaging  techniques  are  powerful  tools  for  the  continuous 
monitoring  of  cellular  processes  in  a  living  animal/tissue  with  a  high  degree  of 
resolution, something not currently possible with all OI techniques. IVM has been 
used  for  measuring  the  heterogeneity  within  tumour  populations  and  interactions 
among subsets  of  cells  within  a  tumour.  It  has  provided  tremendous  insight  into 
various steps of metastasis including cell-cell interactions and the migration of cancer 
cells  [98].  Another  potential  method  for  understanding  the  cellular  processes  of 
metastasis is in vivo video microscopy (IVVM). This provides a dynamic approach to 
visualizing labelled tumour activity within the microcirculation in living animals [99] 
and has provided valuable knowledge in terms of the inefficiency associated with the 
metastatic process [100]. Findings using IVVM have shown that post-extravasation 
growth of individual tumour cells contribute significantly to metastatic inefficiency 
and not  earlier  steps  in  metastasis  as  once previously thought  [101].  While  these 
techniques are certainly promising and can potentially uncover many key processes 
underlying  the  process  of  metastatic  progression,  they  are  time consuming,  often 
require highly sophisticated and expensive imaging systems and do not allow serial 
assessment at secondary sites [93, 95].
2.13. Ex vivo Pulmonary Metastasis Assay
In 1992, Siminski and colleagues first established a method by which 
pulmonary parenchyma could be maintained in serum-free conditions for up to 9 
weeks. This unique ex vivo model system involved cutting murine whole lungs into 
thin slices (~1-2 mm thick) and growing them in culture [102]. This model was later 
adapted and modified by Mendoza et al. to study the influence of the lung 
parenchyma on metastatic osteosarcoma, in an assay they described as a Pulmonary 
Metastasis Assay (PuMA) [93]. The main advantage of this assay over traditional in 
vitro techniques is that it recapitulates the native cellular and microenvironmental 
complexity of the lung within the native 3D lung architecture. It allows valuable 
insight into the progression of metastasis since cellular interactions between cancer 
cells and both the lung parenchyma and ECM are maintained and can be 
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experimentally investigated and/or targeted in an “open box” system, something not 
always feasible in vivo.
2.14. Study Rationale
 Breast cancer remains the leading cause of cancer diagnosis and the second 
leading cause of cancer-related deaths among women. If detected relatively early, 
traditional therapies often prove highly effective. However, many conventional 
therapies fail following the metastatic spread of breast cancer. Thus, the majority of 
deaths associated with breast cancer are due to metastasis, and not the primary 
tumour, particularly in patients with lung metastasis. Previous work in our lab has 
demonstrated that stem-like ALDHhiCD44+ breast cancer cells display preferential 
migration patterns towards lung-derived soluble factors and an increased propensity 
to metastasize to the lung in vivo. However, the exact role of the lung 
microenvironment in supporting growth and progression of breast cancer from a 
single cells stage remains poorly understood.
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3. HYPOTHESIS AND OBJECTIVES
3.1. Hypothesis
 Whole population breast cancer cells exhibit growth and progression within 
an innovative ex vivo pulmonary metastasis (PuMA) model. More specifically, stem-
like ALDHhiCD44+ breast cancer cells demonstrate increased growth and progression 
from a single cell stage to micrometastases to macrometastases within the native lung 
microenvironment in relation to their non stem-like ALDHloCD44- counterparts. 
3.2. Objectives
1. Establish a 3D ex vivo model system for investigating the role of the lung 
microenvironment on breast cancer cell metastatic behaviour. 
2. Evaluate the growth and progression patterns of whole population and 
ALDHhiCD44+ breast cancer cells in the 3D model. 
3. Determine the interaction between lung-derived soluble factor(s) and their 
respective receptors on whole population and ALDHhiCD44+ breast cancer cells. 
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4. MATERIALS AND METHODS
4.1. Cell Culture and Reagents
Commercial cell lines and culturing conditions are listed in Table 1. 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12), 
HAM’S:F12, Modified Eagle Medium alpha (MEM) used for cell culture and 
Medium 199 (M199) used for culturing mouse lung tissue were purchased from 
Invitrogen (Burlington, ON, Canada). Fetal bovine serum (FBS) was purchased from 
Sigma (St. Louis, MO, USA). Tissue culture plates used were purchased from 
NuncTM (Fisher Scientific, Ottawa, ON, Canada). Trypsin was purchased from 
Invitrogen and used at a concentration of 0.25% in citrate saline. Ethylene diamine 
tetraacetic acid (EDTA) was purchased from Bioshop Canada Inc. (Burlington, ON, 
Canada) and used at a concentration of 1 mM in deionized water. Cells were cultured 
and maintained under normal conditions of 37°C and 5% CO2 and used at low 
passages.
4.1.1. Generation of Fluorescent Cell Lines
Cell lines were generated to express tdTomato (excitation 554 nm, emission 
581 nm). MDA-MB-468, SUM149 and MDA-MB-231 breast cancer cell lines were 
transduced with lentivirus containing a tdTomato vector (pLVX-IRES-tdTomato), a 
kind gift from Dr. Hon Sing Leong (London Health Sciences Centre). Stable 
tdTomato-expressing cells were maintained in culture using puromycin (Invitrogen) 
as a selection agent (0.25 μg/mL for MDA-MB-468 and SUM149, 0.5 μg/mL for 
MDA-MB-231).
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Table 1. Cell lines and culturing conditions.  
Cell line/Tissue Culturing conditions Source and References 
SUM149
HAM’S F:12 + 5% FBS, 2.5 mL 
insulin, 500 µL hydrocortisone,      
5 mL HEPES
Asterand Inc. (Detroit, 
MI, USA) [110]
SUM149- 
tdTomato
HAM’S F:12 + 5% FBS, 2.5 mL 
insulin, 500 µL hydrocortisone, 
5 mL HEPES + 0.25 µg/mL 
puromycin
Generated in-house
MDA-MB-231 DMEM:F12 + 10% FBS 
American Type Culture 
Collection (ATCC: 
Manassas, VA, USA) 
[108]
MDA-MB-231-
tdTomato
DMEM:F12 + 10% FBS + 0.5 
µg/mL puromycin
 Generated in-house
MDA-MB-468 MEM + 10% FBS
MD Anderson Cancer 
Center (Houston, TX, 
USA) [109]
MDA-MB-468-
tdTomato
MEM + 10% FBS + 0.25 µg/
mL puromycin
 Generated in-house
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4.2. Fluorescence Activated Cell Sorting
Fluorescence activated cell sorting (FACS) was used to isolate stem-like 
ALDHhiCD44+ and non stem-like ALDHloCD44- subpopulations from both the MDA-
MB-231 and SUM149 breast cancer cell lines. The Aldefluor™ assay kit (StemCell 
Technologies, Vancouver, BC, Canada) was used to assess ALDH activity in cellular 
populations. The Aldefluor™ kit uses an uncharged fluorescent ALDH substrate 
(BODIPY-aminoacetaldehyde (BAAA) that passively diffuses into cells. Cellular 
ALDH activity converts uncharged BAAA molecules to negatively charged BAA- 
molecules, which prevents diffusion out of the cell. The trapped BAA- molecule 
labels ALDHhi cells green. Cells are kept on ice prior to sorting to prevent the active 
efflux of BAA- from labeled cells (Figure 2). Roughly 2 x 108 cells were harvested, 
washed in PBS, centrifuged at 1000g for 5 min, and resuspended in assay buffer. 
Suspended cells were incubated with Aldefluor substrate (1 µL BAAA/106 cells). A 
control sample was also prepared in which diethylaminobenzaldehyde (DEAB; 1.5 
mM), a specific ALDH inhibitor, was co-incubated with Aldefluor. DEAB allows 
BAAA to remain in its uncharged form and therefore passively diffuse out of the cell. 
During FACS analysis, ALDH+ cells were characterized based upon having higher 
levels of fluorescence than the DEAB control. Both Aldefluor only and Aldefluor plus 
DEAB samples were incubated for 50 minutes at 37°C. Following incubation, 
samples were centrifuged (1000g for 5 min), resuspended with provided assay buffer 
and labelled with a CD44-allophycocyanin (APC; BD Biosciences) antibody at 4°C 
for 30 min. Cells were again centrifuged (1000g for 5 min) and resuspended in assay 
buffer. Following resuspension, 7-aminoactinomycin D (7-AAD; BD Biosciences) 
was added to sample tubes for monitoring of cell viability during FACS, and stored 
on ice for immediate transport to the London Regional Flow Cytometry Facility for 
FACS. To remove cellular clumping during transportation, cell suspensions were 
filtered through a 70 µm mesh filter preceding FACS analysis. Sorting was 
accomplished using a 4-colour analysis protocol on a FACSAria I or II (Bd 
Biosciences) at the London Regional Flow Cytometry Facility. ALDH activity  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Figure 2. AldefluorTM Assay. The AldefluorTM assay is a fluorometric assay used to 
detect human cells that express high levels of aldehyde dehydrogenase 1 (ALDH1). The 
fluorescent neutrally charged BODIPY-aminoacetaldehyde (BAAA) molecule is taken up 
by intact and viable cells by passive diffusion. In the presence of ALDH, BAAA is 
converted into BODIPY-aminoacetate (BAA-) which is unable to diffuse out of the cell 
due to its negative charge. Active removal of BAA- by ATP binding cassettes is inhibited 
by the use of provided assay buffer and cold temperature (2-8°C). Resulting fluorescence 
is proportional to ALDH activity and cells can be isolated using a cell sorter. A specific 
inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), is used to control for 
background fluorescence. The population in the DEAB negative control provides an 
appropriate gate for ALDHhi cells, whereby only cells demonstrating higher levels of 
fluorescence than the DEAB control are included.  
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was used as the primary sort criteria (ALDHhi = top 20%, ALDHlo = bottom 20%), 
after which 50% of the ALDHhi cells were selected for the CD44+ phenotype and 50% 
of the ALDHlo cells selected for the CD44- phenotype (Figures 3, 4). The resulting 
isolated ALDHhiCD44+ and ALDHloCD44- populations were transported back to the 
London Regional Cancer Centre and used immediately for injections in the PuMA 
assay.
4.3. Pulmonary Metastasis Assay
4.3.1. Lung Seeding, Harvesting and Culturing
The pulmonary metastasis assay (PuMA) represents an innovative ex vivo 
model for growing sections of lung in culture. This model allows real-time 
assessment of metastatic progression, from single cells to micrometastatic to 
macrometastatic colonies. A main advantage of this assay is that it provides the 
unique ability to study the interactions between cells and the local host 
microenvironment. Serum-free conditions are used for lung culture and were first 
described by Siminski and colleagues [102] and later modified by Mendoza and 
colleagues [93] (Table 2). 
 Healthy  5-7  week  old  female  athymic  nude  mice  (Hsd:  Athymic  Nude-
Foxn1nu; Harlan Sprague-Dawley, Indianapolis, IN) were purchased and maintained 
under  the  guidelines  of  the  Canadian  Council  of  Animal  care  as  outlined  by  the 
protocol  approved by the University of  Western Ontario Council  on Animal Care 
(protocol #2009-064). TdTomato-expressing tumour cells were harvested, suspended 
in either PBS (MDA-MB-468) or Hank’s Balanced Salt Solution (HBSS; Invitrogen) 
(SUM149 and MDA-MB-231) and delivered by tail-vein injection to female athymic 
nude mice. Within 15 minutes of cell injection, mice were euthanized by CO2 
inhalation. Using sterile surgical conditions, the trachea was snipped and cannulated 
with an 18G blunt needle. The lungs were infused under gravitational pressure with 
1.2 mL of equal amounts of well-mixed lung medium 1/low melting agarose solution 
(0.6%, 40°C). The trachea, lungs, and heart were carefully removed en bloc and 
immediately placed in ice-cold PBS containing 100 U/ml penicillin and 100 µg/ml  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Figure 3. Isolation strategy for tdTomato expressing stem-like human breast cancer 
cells from the SUM149 breast cancer cell line. Fluorescence activated cell sorting 
(FACS) was used to isolate both ALDHhiCD44+ and ALDHloCD44- cell populations 
labelled with 7-AAD, CD44-APC and the Aldefluor™ assay kit. Cell subsets were 
isolated using a four-colour protocol on a FACS ARIA I or III and subsequently used for 
the PuMA. (A) Cells were first selected based on expected light scatter, (B) viability 
based on 7-AAD exclusion, (C) and tdTomato positivity. (D) Cells were further divided 
into ALDHhi (top ~20% most positive of ALDH+ population) and ALDHlo (bottom ~20% 
of ALDH+ population) populations. (E) Finally, cells were further selected based on a 
CD44+ phenotype (~50% of the ALDHhi population), or (F) a CD44- phenotype (~50% of 
the ALDHlo population). Resulting subsets were designated as either stem-like 
(ALDHhiCD44+) or non stem-like (ALDHloCD44-) and were used immediately for 
injection into the PuMA.  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Figure 4. Isolation strategy for tdTomato expressing stem-like breast cancer cells 
from the MDA-MB-231 human breast cancer cell line. Fluorescence activated cell 
sorting (FACS) was used to isolate both ALDHhiCD44+ and ALDHloCD44- cell 
populations labelled with 7-AAD, CD44-APC and the Aldefluor™ assay kit. Cell subsets 
were isolated using a four-colour protocol on a FACS ARIA I or III and subsequently 
used for the PuMA. (A) Cells were first selected based on expected light scatter, (B) 
viability based on 7-AAD exclusion, (C) and tdTomato positivity. (D) Cells were further 
divided into ALDHhi (top ~20% most positive of ALDH+ population) and ALDHlo 
(bottom ~20% of ALDH+ population) populations. (E) Finally, cells were further selected 
based on a CD44+ phenotype (~50% of the ALDHhi population), or (F) a CD44- 
phenotype (~50% of the ALDHlo population). Resulting subsets were designated as either 
stem-like (ALDHhiCD44+) or non stem-like (ALDHloCD44-) and were used immediately 
for injection into the PuMA.  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Table 2. Media formulations for lung tissue used in the PuMA. 
Lung Media 1 (perfusion) Lung Media 2 (culturing)
2X M199 Media 1X M199 Media
2.0 μg/mL bovine insulin 1.0 μg/mL bovine insulin
0.2 μg/mL hydrocortisone 0.1 μg/mL hydrocortisone
0.2 μg/mL retinyl acetate 0.1 μg/mL retinyl acetate
200 U/mL penicillin 100 U/mL penicillin
200 μg/mL streptomycin 100 μg/mL streptomycin
7.5% sodium bicarbonate 7.5% sodium bicarbonate
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streptomycin and stored at 4°C for 20 minutes to solidify the medium/agarose 
solution within the lung. Transverse lung sections (1–2 mm in thickness) were cut 
from each lobe using a scalpel blade. This typically gives 12–20 sections per lung. 
Lung sections were carefully placed on a single sterile piece of Gelfoam (~1 cm x 1 
cm) that had been preincubated for 1-2 hours in a 6-well plate with lung medium 2. 
Lung sections were grown in culture for 21 days at 37°C in 5% CO2. Lung medium 2 
was replaced every other day and lung tissue sections turned over carefully with 
tweezers (Figure 5).
4.3.2. Imaging and Analysis of Lung Sections
Seeded sections of lung were imaged at days 0, 7, 14 and 21 post-injection for 
cancer cell growth and progression. Lung sections were first removed from culture on 
their given day and fixed overnight in 10% buffered formalin phosphate (Fisher 
Scientific) plus 25% sucrose (w/v) to preserve fluorescent signal. The following day, 
sections were rinsed with PBS three times and carefully placed on a glass slide with a 
glass coverslip gently sitting on top. Images were acquired using an upright Nikon 
A1R confocal microscope at 20X objective (Nikon), with a 591 nm emission laser 
(Melles Griot, Carlsbad, CA, USA). Three separate lung sections were imaged per 
time point with five images taken per lung section. Growth and progression of 
cellular populations within the lung was determined by measuring the mean 
fluorescent area per field of view (FOV) for each section of lung (µm2) using ImageJ 
software (NIH, Bethesda, WA, USA). Data were normalized to 1000 µm2 at day 0 to 
account for variability in cellular delivery during tail-vein injection. Three mice were 
injected for each cellular population with each replicate using cell populations from 
different days. 
 To determine the relative degree of metastatic progression for each cell 
population, we characterized the percentage of colonies present per image taken as 
either single cells, micrometastatic lesions or macrometastatic lesions according to 
measured diameter. We have set thresholds for single cells as 50 µm or smaller.  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Figure 5. Pulmonary Metastasis Assay (PuMA). The PuMA offers a real time 
assessment of breast cancer cell growth from a single cell stage to multicellular colonies 
in a metastatic setting. (A) Female nude mice are injected tail-vein with tdTomato-
expressing breast cancer cells. (B) Mice are sacrificed 15 min post injection by CO2 
inhalation. The trachea is carefully cut and cannulated with an 18G blunt needle. The 
lungs are infused with an agarose/lung media 1 solution using gravity perfusion. (C) 
Lungs are carefully removed en bloc and cut into ~1 mm transverse sections. (D) Lung 
sections are grown on Gelfoam® pre-incubated with Lung Media 2 and grown in culture 
for 21-days. (E) Sections are removed from the PuMA at days 0, 7, 14 and 21 and fixed 
in formalin for approximately 24 h prior to imaging. Sections are imaged for each time 
point using confocal microscopy to determine metastatic growth, progression and colony 
size. 
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Traditionally, clinical micrometastases in breast carcinoma are defined anywhere 
between 200 µm - 2 mm [103, 104]. We have therefore set the threshold for 
micrometastatic lesions within the PuMA as being between 100-400 µm. There exists 
much less consensus as to what clinically constitutes a macrometastatic lesion and as 
a limitation to the size we can quantitatively measure in a given area of the images 
acquired by confocal microscopy, we have set the threshold for macrometastases as 
anything greater than 400 µm. Using the images taken for growth and progression 
analysis for each time point, we determined the average proportion of colony sizes 
per lung section using ImageJ software (NIH, Bethesda, MD, USA).
4.4. Histology and Immunohistochemistry
Lung sections from the PuMA were fixed for at least 24 h in 10% buffered 
formalin phosphate (Fisher Scientific), paraffin-embedded and sectioned at 5 µm on a 
transverse plain. Hematoxylin and eosin (H&E) staining was carried out by Carl 
Postenka (Histology Research Technician, London Health Sciences Centre). Masson’s 
Trichrome Connective Tissue Stain kit was used according to the manufacturer's 
instructions to evaluate muscle fibre and collagen presence within sections of lung 
(Abcam, Cambridge, MA, USA). Expected Trichrome staining results were as 
follows: collagen (blue), muscle fibres (red) and nuclei (black/blue).  
 Determination of proliferation competency within the PuMA was 
accomplished using Ki-67 staining of seeded lung sections. Sections were rehydrated 
in xylene followed by a series of graded ethanol incubations (100%, 95%, 80%, 
70%). Sections underwent antigen retrieval in sodium citrate buffer (10 mM sodium 
citrate, 0.05% Tween-20, pH 6.0) in a 100°C water bath for 20 min, then cooled at RT 
for an additional 20 min. Staining was performed using the Mouse and Rabbit 
Specific HRP/DAB (ABC) Detection Kit (Abcam) according to the manufacturer’s 
instructions. Purified mouse monoclonal anti-Ki-67 antibody (1:75; Dako, 
Burlington, ON, CA) was diluted in blocking buffer (1% BSA in PBS) and incubated 
with tissue sections in a humid container O/N at 4°C. Detection of bFGF within 
normal unseeded lung sections was accomplished using a rabbit polyclonal anti-FGF 
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basic antibody (1:300; Abcam) which was diluted in blocking buffer (1% BSA in 
PBS) and incubated with tissue sections in a humid container O/N at 4°C. Staining 
was achieved using the same Mouse and Rabbit Specific HRP/DAB (ABC) Detection 
Kit (Abcam). A negative antibody control (no primary) and negative tissue control 
(mouse liver tissue) were used to rule out non-specific binding of primary antibody. 
Following staining for Ki-67 and bFGF, tissues were dehydrated in a series of graded 
ethanol (70%, 80%, 95%, 100%) ending in xylene, mounted with coverslips and 
imaged using the Scanscope® CS System (Aperio, Vista, CA, USA).
4.5. Lung-Conditioned Media, Primary Cell Isolation and Reagents
4.5.1. Animals and Lung Harvesting
Healthy 5-7 week old female athymic nude mice (Hsd: Athymic Nude-
Foxn1nu; Harlan Sprague-Dawley, Indianapolis, IN) were purchased and maintained 
under the guidelines of the Canadian Council of Animal care as outlined by the 
protocol approved by the University of Western Ontario Council on Animal Care 
(protocol #2009-064). Mice were euthanized by CO2 inhalation and their lungs 
removed aseptically. The heart was carefully removed and the lungs were placed in a 
pre-weighed 50 mL conical tube containing 30 mL PBS.
4.5.2. Lung-Conditioned Media Generation
Following the harvesting of lungs (n=4 mice per session), the total weight of 
lungs + PBS was determined using an electronic balance. Harvested lungs were 
washed three times in ice cold PBS before being minced into ~1 mm3 fragments using 
two sterile scalpel blades in a 60 mm2 glass petri dish. Lungs were weight-normalized 
by re-suspension in a 4:1 media to tissue (v/w) ratio in DMEM:F12 supplemented 
with Mito+ serum extender (1X; BD Biosciences, Mississauga, Canada) and 
penicillin-streptomycin (50 U/mL penicillin-50 µg/mL streptomycin; Invitrogen). 
Lung fragments and media were incubated at 37°C and 5% CO2 for 24 h. Following 
incubation, conditioned media (CM) was removed from lung fragments, diluted by a 
further three volumes of media and centrifuged at 1000g for 15 min to remove 
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residual cell debris [43]. CM was filtered by a 0.22 µm syringe filter (Fisher 
Scientific), aliquoted and stored at -80°C until use (Figure 6A).
4.6. Assessment of bFGF Concentration
To measure the concentration of soluble bFGF in lung-CM, the Quantikine® 
ELISA Mouse/Rat FGF Basic Kit was used (R&D Systems, Minneapolis, MN, USA). 
Basal media, lung-CM and lung-CM depleted of bFGF were added to the supplied 
pre-coated microplate and carried out according to the manufacturer's instructions to 
measure the concentration of bFGF in lung-CM and the efficiency of bFGF 
immunodepletion.  
 The Mouse/Rat FGF Basic Kit was also used to determine the concentration 
of soluble bFGF secreted by normal unseeded lung tissue grown in the PuMA. 
Surrounding media and Gelfoam® sections were collected for each time point (days 
0, 7, 14, 21) and centrifuged at 1000g for 10 min to sediment the Gelfoam®. The 
supernatant was collected and added to the microplate and carried through according 
to the manufacturer's instructions to measure the concentration of soluble bFGF at 
each time point throughout the assay. A standard curve was used for each experiment 
and concentrations of bFGF were calculated using a four-parameter logistic (4-PL) 
curve-fit software (elisaanalysis.com/app).
4.6.1. bFGF Immunodepletion from Lung-Conditioned Media
To determine the influence of soluble bFGF on in vitro migration and 
proliferation of breast cancer cells, bFGF was depleted from lung-CM using 
Dynabeads® Protein G (Life Technologies). Lung-CM (1 mL) was added to a 1.5 mL 
microfuge tube with 5 µL of neutralizing monoclonal bFGF antibody (1 mg/mL, 
clone bFM-1; EMD Millipore, Etobicoke, ON, CA). The microfuge tube was inverted 
twice and placed on a nutating mixer (VWR, Radnor, PA, USA) for 30 min at RT. 
Following nutation, Dynabeads® were resuspended in the vial by vortexing for 30 
sec. 50 µL (1.5 µg) Dynabeads® were transferred to a clean 1.5 mL microfuge tube 
and placed in a magnetic rack (Invitrogen) for 2 min to separate beads from solution.  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Figure 6. Lung conditioned media generation and bFGF immunodepletion. (A) 
Healthy female nude mice were euthanized by CO2 inhalation and their lungs removed 
aseptically. Harvested lungs were washed, minced into ~1 mm3 fragments, and 
resuspended in a 4:1 media to tissue (v/w) ratio for incubation at 37°C and 5% CO2 for 24 
h. Following incubation, lung fragments were further diluted by three volumes of media, 
centrifuged and CM filtered prior to use. (B) Immunodepletion of bFGF from lung-CM 
was accomplished using magnetic Protein-G Dynabeads®. I. A neutralizing antibody 
specific to bFGF was added to lung-CM. II. Lung-CM/bFGF antibody was mixed for 30 
min whereby antibody bound free bFGF protein present in lung-CM. III. Lung-CM/bFGF 
antibody mixture was added to magnetic Dynabeads® and mixed for 20 min. IV. After 
mixing, a magnet was used to separate lung-CM from the bFGF antibody/Dynabeads® 
mixture. 
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The supernatant was carefully removed and 1 mL of lung-CM/bFGF antibody 
mixture was added to the magnetic beads. The lung-CM/bFGF antibody/beads 
solution was inverted twice and placed on a nutating mixer for 20 min at RT. After 
mixing, the tube was placed in a magnetic rack for 2 min to separate lung-CM from 
the bFGF antibody-beads mixture. Lung-CM depleted of bFGF was transferred to a 
new tube and filtered by 0.22 µm syringe filtration (Fisher Scientific), aliquoted and 
stored at -80°C until use (Figure 6B). For bFGF rescue experiments involving re-
addition of bFGF to immunodepleted lung-CM, recombinant bFGF (Sigma) at a 
concentration of 0.3 µg/mL was added to depleted media prior to cell seeding. This 
amount was equal to the concentration of bFGF determined to be present in normal 
lung-CM. 
4.7. In vitro Transwell Migration Assay
Patterns of MDA-MB-231 and SUM149 whole population cellular migration 
towards lung-CM were assessed using transwell migration assays. Prior the start of 
the assay, 300 µL of gelatin (Bioshop) was warmed to 60°C for 20 min and further 
diluted with 1500 µL of sterile water. Transwell inserts (24-well, 6.4 mm 
polyethylene terephthalate membrane, 8 µm pore size; BD Falcon, Mississauga, ON, 
CA) were then coated with diluted gelatin (6 µg/well) and allowed to dry at RT in a 
sterile environment O/N. Immediately prior to the assay, gelatin was reconstituted 
with control media (DMEM:F12 + Mito+ + 0.1% BSA; Bioshop) and agitated for 1.5 
h at RT. Following reconstitution, SUM149 or MDA-MB-231 whole cell populations 
were harvested, washed twice with PBS and suspended at a concentration of 5 x 105 
cells/mL in control media. Excess media from the top of the transwells was carefully 
removed with a pipette and 600 µL of negative basal media, lung-CM or lung-CM 
depleted of bFGF was added to the bottom wells of a 24-well dish. Cells (5 x 104 
cells/mL) were seeded onto the top portion of each transwell chamber. Chambers 
containing cells were placed on top of the wells containing chemoattractant and 
incubated for 18 h at 37°C, 5% CO2. Following incubation, transwell chambers were 
removed, inverted and fixed with 1% gluteraldehyde (Fisher Scientific) in PBS for 20 
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min. Fixed cells were washed with sterile water and 0.1% Triton-X-100 (Acros 
Organics, NJ, USA) in PBS for 10 min. Cells were washed again with sterile water 
and non-migrated cells were removed from the inner portion of the transwell chamber 
with a cotton swab. Membranes were carefully cut out from the transwell chambers, 
placed on a microscope slide and mounted with Vectashield with DAPI (Vector 
Laboratories, Burlingame, CA, USA). Five high powered fields of view (FOV) were 
captured for each well, and a mean number of migrated cells/FOV was calculated 
using ImageJ software.
4.8. In vitro BrdU Incorporation Assay
Proliferative responses of the human breast cancer cell lines SUM149 and 
MDA-MB-231 to human lung-CM were assessed using a bromodeoxyuridine (BrdU) 
incorporation assay. Whole population (1.5 x 104/well) were plated on 8-well 
chamber slides (Lab-tek; Fisher Scientific) and allowed to adhere for 24 h, after 
which cells were washed once with PBS and serum starved for 72 h. Media was then 
replaced with lung-CM, negative control media (basal media; DMEM:F12 + Mito+), 
or positive control media (DMEM:F12 + Mito+ + 10% FBS) for 24 h. Following 
incubation, BrdU (5 µg/mL; Amersham Cell Proliferation Labelling Reagent; GE 
Healthcare, Piscataway, NJ, USA) was added for 30 min. Following BrdU 
incorporation, cells were washed with PBS and fixed with 10% neutral-buffered 
formalin (Fisher Scientific) for 5 min. Cells were then incubated with 0.1% Triton 
X-100 (Sigma) in PBS for 10 min to permeabilize cell membranes and subsequently 
treated with 2N HCl (Fisher Scientific) for 10 min to denature DNA. Slides were 
blocked for 30 min in 5% bovine serum albumin (BSA) in 0.1% Triton X-100 in PBS. 
An anti-BrdU primary antibody (BD Biosciences) was added (1:75 dilution) in 5% 
BSA/0.1% Triton X-100 in PBS for 1 h at RT. Slides were washed with PBS and a 
FITC-conjugated anti-mouse IgG secondary antibody (H+L made in horse; Vector, 
Burlington, ON, Canada) was added (1:100 dilution) in 5% BSA + 0.1% Triton 
X-100 in PBS for 1 h at RT. Slides were washed with PBS to remove unbound 
antibody, mounted with ProLong Gold with DAPI (Invitrogen) and allowed to cure 
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O/N in the dark at RT. Images were taken (5 FOV/well) and nuclei counted using 
ImageJ. Results were expressed as a percentage of BrdU positive cells to total nuclei.
4.9. Blocking of bFGF and CD44 in the PuMA
To determine the effect of bFGF present within the lung microenvironment in 
the context of the PuMA, antibody mediated blocking of either bFGF alone or its 
non-canonical receptor, CD44 was used. Highly aggressive MDA-MB-231 breast 
cancer cells were chosen as they were shown to progress to the greatest degree within 
the PuMA. TdTomato-expressing MDA-MB-231 whole population cells were 
harvested and first split into two groups: one group incubated at RT for 30 min in 
HBSS and the other to incubate at RT in the presence of a rat monoclonal anti-CD44 
antibody (1:50; Abcam) in HBSS for 30 min (Figure 7A). Following incubation, cells 
were delivered  to female nude mouse lungs by tail vein injection (5 x 105 cells/
mouse, n=3 mice) (Figure 7B). Lungs seeded with cells pre-incubated with an anti-
CD44 antibody were infused with the normal agarose/lung media 1 solution and 
excised as per the PuMA protocol. Lungs seeded with cells not pre-incubated with 
HBSS only were either infused with the normal agarose/lung media 1 solution or 
agarose/media 1 solution plus a neutralizing monoclonal bFGF antibody (1:200, clone 
bFM-1; EMD Millipore) before following the remainder of the PuMA protocol 
(Figure 7C). Sections were cultured in serum-free conditions for 21 days, removed 
from culture on their given day (0, 7, 14, 21) and fixed O/N in 10% buffered formalin 
phosphate (Fisher Scientific) plus 25% sucrose (w/v) to preserve fluorescent signal. 
The following day, sections were imaged for cancer cell growth and progression. 
Three separate lung sections were imaged per time point with five images taken per 
lung section. Growth and progression of cellular populations within the lung was 
determined by measuring the mean fluorescent area per FOV for each section of lung 
(µm2) using ImageJ software (NIH). Data were normalized to 1000 µm2 at day 0 to 
account for variability in cellular delivery during tail-vein injection. Three mice were 
injected for each experimental group using cell populations from different days.  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Figure 7. Blocking strategy for bFGF and CD44 in the PuMA. Both bFGF and CD44 
were blocked to determine the effect of bFGF on breast cancer cell growth in the context 
of the PuMA. (A) TdTomato-expressing MDA-MB-231 whole population cells were 
harvested and either incubated in HBSS or incubated in the presence of an anti-CD44 
antibody in HBSS. (B) Following incubation, cells were delivered female nude mouse 
lungs by tail vein injection. (C) Lungs seeded with cells pre-incubated with an anti-CD44 
antibody were infused with the normal agarose/media 1 solution. Lungs seeded with cells 
not pre-incubated with an anti-CD44 body were either infused with the normal agarose/
media 1 solution or in agarose/media 1 solution plus a neutralizing bFGF antibody. 
Resulting lungs were sliced into transverse sections and grown in culture according to the 
PuMA. 
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4.10. Statistical Analysis
 All experiments were performed using a minimum of three biological 
replicates with internal triplicates, unless otherwise noted. Statistical analysis was 
done using GraphPad Prism 6.0 (San Diego, CA, USA) and data are presented as 
mean ± standard error of the mean (SEM). A one-way analysis of variance (ANOVA) 
was used to compare data with multiple means and a two-way ANOVA used to 
compare multiple means between different groups. Either a Dunnet’s, Tukey’s or 
Bonferroni, or Sidak’s post-hoc test was used to confirm significance, as noted. P-
values less than 0.05 were deemed statistically significant.
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5. RESULTS
5.1. Pulmonary Architecture Remains Structurally and Microscopically 
Intact in the PuMA over 21 days
The PuMA represents an innovative model to study the behaviour of cancer 
cells within the lung microenvironment in an open-box manner. We first wanted to 
determine if sections of female nude mouse lungs could remain viable and healthy 
throughout the duration of the PuMA. Unseeded slices of lung from healthy mice 
were maintained according to the PuMA protocol. Lung slices were fixed, paraffin 
embedded,  sectioned  and  stained  at  days  0,  7,  14  and  21  with  H&E for  routine 
histological examination and Masson’s Trichrome stain to evaluate connective tissue 
components  (Figure  8).  H&E  staining  demonstrated  that  the  lung  remained 
structurally intact with normal lung appearance throughout the 21 day period. Alveoli 
were uniformly expanded throughout the lung for the duration of the assay with no 
evidence of alveolar collapse. A thin outline of solidified agarose could be identified 
within  the  alveoli  and  larger  airways,  which  indicated  successful  infusion  of  the 
agarose/media solution prior to the start  of the PuMA. Alveoli,  airways and large 
vessels  remained  expanded  with  no  evidence  of  collapse  seen  in  the  pulmonary 
architecture. Both type I and type II pneumocytes were present at each time point 
throughout the assay and could be appropriately identified. There was a decrease in 
overall cellularity as evidenced by a qualitative reduction in total nuclei present at 
days  14  and  21  compared  to  earlier  time  points.  However,  the  overall  lung 
microarchitecture was remarkably unchanged throughout the duration of the assay 
(Figure  8A).  Sections  of  unseeded  lung  from the  PuMA were  also  stained  with 
Masson’s Trichome stain to evaluate the presence of  connective tissue during the 
PuMA. Over the course of 21 days, muscle tissue was present surrounding arteries 
and larger airways. Collagen fibres could also be identified at each time point and 
were present surrounding vasculature. Although collagen was present throughout the  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Figure 8. Pulmonary architecture remains structurally and microscopically intact 
in the PuMA over 21 days. To demonstrate the viability of the PuMA, normal unseeded 
female mouse lungs were cultured according to the PuMA, fixed, paraffin embedded, 
sectioned and stained. (A) H&E staining revealed the lung microarchitecture remained 
relatively healthy and intact throughout the 21 day period. Alveoli (A), airways (B) and 
large vessels (PA, pulmonary arteries; PV, pulmonary veins) throughout the lung 
remained expanded and were of normal diameter. Overall, gross cellularity decreased at 
days 14 and 21 compared to earlier time points. (Inset) Type I (blue arrows) and type II 
(blue arrowheads) pneumocytes were present at each time point throughout the assay 
and could be identified. Scale bar: 25 µm. (B) Masson’s Trichome stain was used to 
evaluate connective tissue components in the lung. Over the course of 21 days, muscle 
tissue (red stain) and collagen tissue (blue stain) remained visibly present with a slight 
reduction in collagen staining at day 21. Each component was present and could be 
identified at each time. Scale bars: 200 µm. 
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duration of the assay, there appeared to be a slight reduction in collagen staining by 
day 21 relative to earlier time points (Figure 8B). Each of these components was 
present and could be identified at each time point.
5.2. Whole Population MDA-MB-468, SUM149 and MDA-MB-231 Breast 
Cancer Cell Lines Demonstrate Differential Growth Progression Within 
the PuMA 
To first determine the growth potential of whole population breast cancer cells 
within the lung, we used three different breast cancer cell line models with varying 
degrees  of  metastatic  behaviour  in  vivo:  very  weakly  metastatic  MDA-MB-468, 
weakly metastatic SUM149 and highly metastatic MDA-MB-231 breast cancer cells. 
Cells were delivered to female nude mouse lungs by tail vein injection according to 
the PuMA protocol. Sections were cultured in serum-free conditions for 14 days and 
imaged at days 0, 7 and 14 using confocal microscopy to evaluate cellular growth and 
progression.  Only  SUM149  and  MDA-MB-231  cells  demonstrated  increased 
fluorescence area at later time points compared to earlier time points (Figure 9B,C), 
whereas very weakly metastatic MDA-MB-468 cells failed to progress into larger 
colonies  (Figure  9A).  Highly  metastatic  MDA-MB-231  cells  showed  a  greater 
progression in growth area compared to the weakly metastatic SUM149 cell  line. 
Single cells could be seen in sections of lung in similar numbers at day 0 for each cell 
line, demonstrating successful delivery of cells to the lungs. Single cells progressed 
during the assay to small multicellular colonies by day 7 (SUM149, MDA-MB-231) 
and even larger colonies by day 14 (MDA-MB-231). However, little to no growth 
was observed for the very weakly metastatic MDA-MB-468 cell line over 14 days 
(Figure 9B, C, D). Cellular growth of SUM149 cells indicated by fluorescent area 
was significantly increased at day 7 (p≤0.05) and 14 (p≤0.001) relative to day 0, and 
day 14 (p≤0.01) relative to day 7 (Figure 9E). Growth of MDA-MB-231 cells was 
significantly increased at day 14 relative to days 7 (p≤0.05) and 0 (p≤0.01) (Figure 
9F). Statistical significance was determined by one-way ANOVA with a Tukey’s post 
test. Error bars represent ± SEM.
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Figure 9. Whole population MDA-MB-468, SUM149 and MDA-MB-231 human 
breast cancer cells differentially progress within the PuMA. To determine if breast 
cancer cells were able to grow and progress within the PuMA, very weakly metastatic 
MDA-MB-468, weakly metastatic SUM149 and highly metastatic MDA-MB-231 breast 
cancer cells were injected (n=3 mice). (A, B, C) Representative images for each cell line 
are shown. Five random images were taken for each of three lung sections for each time 
point. Single cells are seen within the lung at day 0, which progress to multicellular 
colonies by day 7 and 14 in the SUM149 and MDA-MB-231 populations only. Scale bars 
represent 100 µm. A mean normalized fluorescent area (µm2) per image was measured 
and averaged for each time point. (D) MDA-MB-468 cells fail to grow into larger 
colonies. (E) SUM149 cell growth increased at day 7 (p≤0.05) and 14 (p≤0.001) relative 
to day 0, and day 14 (p≤0.01) relative to day 7. (F) MDA-MB-231 cell growth increased 
at day 14 relative to days 7 (p≤0.05) and 0 (p≤0.01). * indicates statistical significance. 
Error bars represent ± SEM.  
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5.3. Highly Metastatic MDA-MB-231 Cells Proliferate in the PuMA 
To  assess  the  proliferative  competency  of  breast  cancer  cells  within  the 
PuMA,  sections  of  lung  seeded  with  highly  metastatic  MDA-MB-231  whole 
population cells were fixed, sectioned and stained for the proliferative marker, Ki-67. 
Positive Ki-67 staining was present at day 0 once cells had arrived to the lung and 
throughout the duration of the assay (days 7, 14). Positive staining for Ki-67 was 
most notable at day 14 in larger multicellular colonies (Figure 10B). Positive staining 
was compared to a negative control (unseeded lung section from PuMA at day 14) 
(Figure 10A). Serial sections from the same lung tissue from each time point were 
also stained with H&E to confirm proliferative competency of breast  cancer cells 
(versus surrounding lung tissue). Indeed, H&E staining demonstrated a concentrated 
presence of tumour cells corresponding to areas of Ki-67 positivity. Similar to Ki-67 
staining,  the  most  notable  areas  of  tumour cells  were seen in  larger  multicellular 
colonies  at  day  14  relative  to  earlier  time  points  (Figure  10C).  To  qualitatively 
determine if these areas of tumour cells seen in seeded sections of lung were in fact 
areas  of  tumour  cells,  seeded H&E sections  were  compared to  an unseeded lung 
section from the PuMA at day 14 (Figure 10A).
5.4. Stem-like ALDHhiCD44+ MDA-MB-231 Breast Cancer Cells Progress 
Relative to ALDHloCD44- Cells within the PuMA 
After  demonstrating  the  ability  of  whole  breast  cancer  cell  populations  to 
grow within the lung in the PuMA, we wanted to determine the growth differences 
between stem-like and non stem-like breast cancer cells. To assess growth patterns of 
weakly  aggressive  SUM149 and highly  aggressive  MDA-MB-231 cells,  both  cell 
lines underwent FACS to isolate both stem-like ALDHhiCD44+ and non stem-like 
ALDHloCD44- populations. Immediately following isolation, 5 x 105 ALDHhiCD44+ 
or ALDHloCD44- tdTomato-expressing SUM149 or MDA-MB-231 breast cancer cells 
were delivered to female mouse lungs by tail vein injection (n=3 mice) and cultured 
for 21 days following the PuMA protocol. Initial cellular delivery was similar for 
both stem-like and non stem-like populations for each cell line injected. Single cells 
were present  within the lung at  day 0 for  both ALDHhiCD44+ and ALDHloCD44- 
populations in each cell line. Weakly aggressive SUM149 ALDHhiCD44+ cells  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Figure 10. Highly metastatic MDA-MB-231 proliferate in the PuMA. To assess the 
proliferative competency of breast cancer cells grown in the PuMA, both normal 
unseeded and seeded sections of lung with highly aggressive MDA-MB-231 cells were 
stained for the proliferative marker Ki-67. (A) Negative control for both Ki-67 and H&E 
staining (unseeded lung section from day 14 in PuMA). (B) Seeded sections of lung with 
highly aggressive MDA-MB-231 cells in the PuMA show positive staining for Ki-67 in 
cells present in the lung at day 0 through day 14. Positive staining is most notable at day 
14. (C) H&E staining of serial sections of seeded lungs confirmed proliferative 
competency of highly metastatic cells within the PuMA, as seen with Ki-67 staining. 
Scale bars represent 50 µm. 
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Figure 11. Stem-like ALDHhiCD44+ MDA-MB-231 breast cancer cells progress 
relative to ALDHloCD44- cells within the PuMA. To determine growth patterns 
between stem-like and non stem-like breast cancer cells in the PuMA, ALDHhiCD44+ and 
ALDHloCD44- cells were isolated by FACS from SUM149 and MDA-MB-231 human 
breast cancer cell lines and injected into the PuMA (n=3 mice). (A, B) Representative 
images for each population are shown. Five random images were taken per lung section 
(n=3 lung sections) for each time point. Single cells are seen within the lung at day 0 for 
both populations, which progress to increasingly larger multicellular colonies by day 21 
only in the stem-like ALDHhiCD44+ population. Scale bars represent 100 µm. A mean 
normalized fluorescent area (µm2) per FOV was measured and averaged for each time 
point. (C) SUM149 cellular growth was increased in the ALDHhiCD44+ population 
relative to the ALDHloCD44- population at day 14 (p≤0.05) and day 21 (p≤0.0001). (D) 
MDA-MB-231 growth was increased in the ALDHhiCD44+ population compared to the 
ALDHloCD44- population at day 14 (p≤0.001) and day 21 (p≤0.0001). * indicates 
statistical significance between stem-like and non stem-like populations at a given time 
point. Error bars represent ± SEM. 
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progressed  to  small  multicellular  colonies  by  day  21,  whereas  non  stem-like 
ALDHloCD44- cells remained predominantly as single cells throughout the duration 
of  the  assay  (Figure  11A).  Highly  aggressive  MDA-MB-231  stem-like 
ALDHhiCD44+  cells  progressed  to  much  larger  multicellular  colonies  by  day  21 
compared to non stem-like ALDHloCD44- cells which remained primarily as single 
cells. Scale bars represent 100 μm (Figure 11B). SUM149 cellular growth increased 
in the ALDHhiCD44+ population relative to the ALDHloCD44- population at day 14 
(p≤0.05)  and  day  21  (p≤0.0001)  (Figure  11C).  Similarly,  MDA-MB-231  cellular 
growth increased in the ALDHhiCD44+ population compared to the ALDHloCD44- 
population at day 14 (p≤0.001) and day 21 (p≤0.0001) (Figure 11D). Significance 
between both populations at a given time point was determined by two-way ANOVA 
with a Sidak’s post test. Error bars represent ± SEM.
5.5. ALDHhiCD44+ Breast Cancer Cells Progress from Single Cells to 
Micrometastases to Macrometastases in the PuMA while the Majority of 
ALDHloCD44- Cells Remain as Single Cells
To further  quantify the differences in progression within the lung between 
stem-like ALDHhiCD44+ and non stem-like ALDHloCD44-  breast  cancer  cells,  we 
measured and classified the size of colonies present in the PuMA. Three groups were 
used to classify the sizes of multicellular colonies in the PuMA according to diameter: 
diameter: single cells (≤50 µm), micrometastases (100-400 µm) or macrometastases 
(>400 µm). Data were presented as a mean percentage of specific colony size (single 
cells,  micrometastases,  or  macrometastases)  per  image.  Stem-like  ALDHhiCD44+ 
cells from the weakly metastatic SUM149 cell line progressed from single cells at day 
0  (100.0%  ±  0.0  single  cells,  0.0%  ±  0.0  micrometastases,  0.0%  ±  0.0 
macrometastases) to micrometastases by day 21 (89.3% ± 4.7 single cells, 10.7 % ± 
2.6 micrometastases, 0.0% ± 0.0 macrometastases). In contrast, the majority of non 
stem-like ALDHloCD44- cells  remained as single cells  from day 0 (100.0% ± 0.0 
single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0 macrometastases) throughout 
the  duration  of  the  assay  to  day  21  (98.0%  ±  2.0  single  cells,  1.3%  ±  1.3 
micrometastases, 0.0% ± 0.0 macrometastases) (Figure 12A, Table 3). As predicted, 
Highly aggressive MDA-MB-231 stem-like ALDHhiCD44+ cells grew to a greater  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Figure 12. ALDHhiCD44+ breast cancer cells progress from single cells to micromets 
to macromets while the majority of ALDHloCD44- cells remain as single cells. 
Colonies present in lung sections grown in the PuMA were classified in diameter as 
single cells (≤50 µm), micromets (100-400 µm) or macromets (>400 µm). Five random 
images were taken per lung section (n=3 lung sections) for each time point. (A) Only 
SUM149 ALDHhiCD44+ cells progressed from single cells at day 0 to micromets. (B) 
MDA-MB-231 ALDHhiCD44+ cells progressed from single cells at day 0 through 
micromets to macromets whereas ALDHloCD44- cells remained predominantly as single 
cells. 
0 7 14 21
0
20
40
60
80
100
120
Day (post injection)
Pe
rc
en
ta
ge
 o
f c
ol
on
ie
s 
co
un
te
d 
pe
r F
O
V
Single cells
Micromets
Macromets
M
DA
-M
B-
23
1
SU
M
14
9
0 7 14 21
0
20
40
60
80
100
120
Day (post injection)
Pe
rc
en
ta
ge
 o
f c
ol
on
ie
s 
co
un
te
d 
pe
r F
O
V
Single cells
Micromets
Macromets
0 7 14 21
0
20
40
60
80
100
120
Day (post injection)
Pe
rc
en
ta
ge
 o
f c
ol
on
ie
s 
co
un
te
d 
pe
r F
O
V
Single cells
Micromets
Macromets
0 7 14 21
0
20
40
60
80
100
120
Day (post injection)
Pe
rc
en
ta
ge
 o
f c
ol
on
ie
s 
co
un
te
d 
pe
r F
O
V
Single cells
Micromets
Macromets
A
B
ALDHhiCD44+ALDHloCD44-
Single cells
Micrometastases
Macrometastases
!49
Table 3. Proportion of SUM149 ALDHhiCD44+ and ALDHloCD44- colony sizes in 
the PuMA.   
Bold Font = Stem-like ALDHhiCD44+ population 
Regular Font = Non stem-like ALDHloCD44- population  
Day 0 Day 7 Day 14 Day 21
Single cells  
(<50 µm)
100.0 ± 0.0                          
100.0 ± 0.0
98.7 ± 0.3                          
100.0 ± 0.0
95.7 ± 0.9                          
100.0 ± 0.0
89.3 ± 4.7                          
98.0 ± 2.0
Micromets 
(100-400 µm)
0.0 ± 0.0               
0.0 ± 0.0
1.3 ± 2.6               
0.0 ± 0.0
4.3± 0.3                          
0.0 ± 0.0
10.7 ± 2.6                          
1.3 ± 1.3
Macromets 
(>400 µm)
0.0 ± 0.0                 
0.0 ± 0.0
0.0 ± 0.0                 
0.0 ± 0.0
0.0 ± 0.0                          
0.0 ± 0.0
0.0 ± 0.0                         
0.0 ± 0.0
!50
proportion of larger multicellular colonies compared to weakly aggressive SUM149 
cells.  MDA-MB-231  ALDHhiCD44+  cells  progressed  from  single  cells  at  day  0 
(100.0% ± 0.0 single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0 macrometastases) 
through micrometastases to macrometastases by day 21 (58.0% ± 2.0 single cells, 
24.0% ± 2.2  micrometastases,  17.7% ± 4.3  macrometastases).  Similar  to  patterns 
observed  with  SUM149  cells,  non  stem-like  MDA-MB-231  ALDHloCD44-  cells 
remained mainly as single cells  throughout the duration of the assay.  Single cells 
present at day 0  (100.0% ± 0.0 single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0 
macrometastases) progressed to few micrometastasis sized colonies by 21 (93.0% ± 
2.5 single cells, 6.7% ± 2.9 micrometastases, 0.3% ± 0.3 macrometastases) (Figure 
12B, Table 4). Overall, stem-like ALDHhiCD44+ cells isolated from both cell lines 
progressed to larger sized colonies by day 21 faster and in greater numbers compared 
to their non stem-like ALDHloCD44- counterparts.
5.6. Basic Fibroblast Growth Factor is Present in Lung-conditioned Media 
and Increases in vitro Breast Cancer Cell Proliferation, but not Migration
Previous work in our lab has identified the presence of many lung-derived 
soluble factors present in the lung microenvironment that could potentially contribute 
to the metastatic behaviour of breast cancer cells. Many of these soluble factors are 
proteins  that  have  well-characterized  roles  in  cellular  adhesion,  migration  and 
neoplasia. In addition, many of the soluble factors identified in the lung are CD44-
associated proteins [52]. One specific protein of interest previously identified is basic 
fibroblast growth factor (bFGF) due to its potent mitogenic effect, well-characterized 
role in the maintenance of normal stem cells and its interaction with the cell surface 
receptor, CD44 [83, 105]. Therefore, we wanted to determine the influence of bFGF 
on breast cancer cell migration and proliferation. Conditioned media was generated 
from healthy female mouse lungs, bFGF protein levels were assessed, and bFGF was 
removed from lung CM by means of immunodepletion (Figure 13). bFGF protein 
levels were determined by ELISA in basal media (BM), lung-CM, lung-CM exposed 
to Dynabeads Protein G only, and lung-CM exposed to Dynabeads plus an anti-mouse 
bFGF antibody. Data indicated that the concentration of bFGF present in lung-CM 
was significantly higher than bFGF present in BM (p≤0.0001). Immunodepletion of  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Table 4. Proportion of MDA-MB-231 ALDHhiCD44+ and ALDHloCD44- colony sizes 
in the PuMA. 
Bold Font = Stem-like ALDHhiCD44+ population 
Regular Font = Non stem-like ALDHloCD44- population  
Day 0 Day 7 Day 14 Day 21
Single cells  
(<50 µm)
100.0 ± 0.0                          
100.0 ± 0.0
83.0 ± 4.0                          
98.7 ± 0.9
74.3 ± 1.5                          
96.0 ± 2.5
58.0 ± 2.5                          
93.0 ± 2.5
Micromets 
(100-400 µm)
0.0 ± 0.0               
0.0 ± 0.0
17.3 ± 3.8               
1.3 ± 0.9
25.0 ± 1.2                          
4.0 ± 2.5
24.0 ± 2.2                          
6.7 ± 2.9
Macromets 
(>400 µm)
0.0 ± 0.0                 
0.0 ± 0.0
0.0 ± 0.0                 
0.0 ± 0.0
0.7 ± 0.3                          
0.0 ± 0.0
17.7 ± 4.3                         
0.3 ± 0.3
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bFGF was successful  and resulted in lung-CM with significantly decreased bFGF 
levels compared to lung-CM alone (p≤0.0001). These levels were in line with the BM 
control. Dynabeads Protein G only in the absence of an anti-bFGF antibody had no 
effect  on  bFGF  depletion  (Figure  13A).  Data  are  presented  as  mean  bFGF 
concentration ± SEM (n = 3). To assess the influence of lung-derived bFGF on breast 
cancer cell migration, whole population SUM149 or MDA-MB-231 cells were plated 
in  triplicate  on  top  of  gelatin-coated  transwells.  Transwells  were  placed  in  basal 
media (DMEM:F12 + Mito+), normal lung-CM or lung-CM depleted of bFGF and 
incubated  for  18  hr  at  37°C and  5% CO2.  SUM149 cells  showed a  significantly 
increased number of migrated cells exposed to lung-CM relative to BM (p≤0.01), 
although this migration was not impacted by depletion of bFGF (Figure 13B). MDA-
MB-231 cells demonstrated a similar pattern to SUM149 cells with a significantly 
increased number of migrated cells exposed to lung-CM relative to BM-, with no 
influence of bFGF (p≤0.001) (Figure 13C). 
To determine the influence of bFGF on cellular proliferation, SUM149 or MDA-
MB-231 cells were plated in triplicate in 8-well chamber slides and incubated for 24 
hr at 37°C and 5% CO2 (n = 3) prior to incubation with BrdU. SUM149 cells showed 
a significantly increased number of BrdU positive cells when exposed to lung-CM 
relative to BM- (p≤0.0001), and this effect could be abrogated by depletion of bFGF 
(p≤0.0001) to levels consistent with the BM- control (Figure 13D). MDA-MB-231 
cells  displayed  similar  BrdU  incorporation  patterns  to  SUM149  cells,  with  a 
significantly increased number of BrdU positive cells exposed to lung-CM relative to 
BM (p≤0.001) and abrogation of  this  effect  with depletion of  bFGF (p≤0.001) to 
levels consistent with the BM control (Figure 13E). To determine if bFGF was in fact 
increasing cellular proliferation, recombinant bFGF was added to immunodepleted 
lung-CM.  The  re-addition  of  bFGF  to  immunodepleted  lung-CM  rescued  the 
reduction of cellular proliferation to levels consistent with non-depleted lung-CM. 
This effect was apparent in both SUM149 and MDA-MB-231 cell lines.
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Figure 13. Depletion of bFGF from lung conditioned media reduces breast cancer 
cell proliferation but not migration. To determine the effect of bFGF on breast cancer 
cell migration and proliferation, bFGF was immunodepleted from lung-CM. (A) CM was 
generated from healthy female mouse lungs and bFGF immunodepleted. Resulting bFGF 
protein levels were determined by ELISA in basal media (BM), lung-CM, lung-CM 
exposed to Dynabeads only, and lung-CM exposed to beads plus an anti-mouse bFGF 
antibody. Data indicate bFGF is present in lung-CM and not in BM (p≤0.0001). 
Immunodepletion of bFGF from lung-CM was successful (p≤0.0001). Data are presented 
as mean bFGF concentration ± SEM (n = 3). (B, C) SUM149 and MDA-MB-231 cells 
showed an increased number of migrated cells exposed to lung-CM relative to BM 
(p≤0.01, p≤0.001). No migratory differences are seen for cells exposed to lung-CM 
compared to lung-CM depleted of bFGF. (D, E) SUM149 and MDA-MB-231 cells show 
a significantly increased number of BrdU positive cells exposed to lung-CM relative to 
BM (p≤0.0001, p≤0.001). SUM149 and MDA-MB-231 cells exposed to lung-CM 
depleted of bFGF (ΔbFGF) showed significantly less BrdU positive cells compared to 
lung-CM (p≤0.0001, p≤0.001). Re-addition of recombinant bFGF to depleted lung-CM 
(ΔbFGF/bFGF) rescued the effect on proliferation for both cell lines to levels consistent 
with lung-CM alone. * indicates statistical significance. Data are presented as mean 
number of migrated cells/FOV or percentage of BrdU positive cells per total cells 
counted ± SEM (n = 3). 
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5.7. Basic Fibroblast Growth Factor is Present in the Intact Lung 
Microenvironment
To  further  determine  the  presence  of  bFGF  within  the  intact  lung 
microenvironment in the context  of  the PuMA, sections of normal unseeded lung 
from healthy mice were immunohistochemically stained for bFGF at each time point 
of the assay (days 0, 7, 14, 21) (Figure 14A). Sections of lung were grown in culture 
according to the PuMA protocol, fixed, paraffin embedded and sectioned into 5 μm 
slices for staining with an anti-mouse bFGF antibody. Unseeded sections of lung in 
the PuMA consistently showed diffuse positive staining for bFGF at day 0 through 
day  21.  The  highest  levels  of  staining  for  bFGF  corresponded  to  the  basement 
membrane surrounding vasculature within the lung. A negative control stained with 
secondary antibody only was used to assess any non-specific binding of secondary 
antibody.  Furthermore,  tissue  from  mouse  liver  was  also  used  as  a  control  to 
determine if  the anti-bFGF antibody simply bound to any tissue of mouse origin. 
Staining shows that there is very weak signal for bFGF present in the liver whereas 
signal in the lung is diffusely present throughout the tissue.
To further evaluate the presence of bFGF in the context of the PuMA, surrounding 
media and Gelfoam® were collected for each time point in the PuMA  on which 
normal unseeded sections of lung were grown (Figure 14B). Media and Gelfoam® 
were centrifuged together and the supernatant collected to measure the concentration 
of secreted mouse bFGF by ELISA. Basal media (M199 media) alone contained no 
soluble bFGF and day 0 contained negligible amounts of bFGF. By day 7, a small 
amount of bFGF is present in the Gelfoam® and surrounding media. At days 14 and 
21, this amount is more pronounced, with a significant increase in bFGF at day 14 
relative to day 0 (p≤0.05) and media only (p≤0.05), and day 21 relative to day 0 
(p≤0.05) and media alone (p≤0.05). This increase coincided with the length of time 
that  lung sections  spent  on the  Gelfoam® throughout  the  duration of  the  PuMA. 
Statistical significance at a given time point was determined by one-way ANOVA 
with a Tukey’s post test. Data was presented as bFGF concentration (μg/mL) ± SEM.
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Figure 14. Basic fibroblast growth factor is present in the intact lung 
microenvironment. To determine the presence of bFGF within the lung in the context of 
the PuMA, sections of normal unseeded lung grown in the PuMA were 
immunohistochemically stained for bFGF. (A) Unseeded sections of lung consistently 
show diffuse positive staining for bFGF at days 0 through day 21. Positive staining is 
most notable around the basement membranes of airways and vasculature (black arrow). 
A antibody negative control consisted of the section stained with secondary antibody 
only. Mouse liver tissue was used as a tissue control to determine the specificity of the 
anti-bFGF antibody. Scale bars represent 200 µm. (B) Surrounding media/Gelfoam® 
were collected for each time point in the PuMA which normal sections of lung were 
grown. Basal media (BM) alone contained no soluble bFGF and day 0 contained 
negligible amounts. By day 7, a small amount of bFGF is present in the Gelfoam and 
surrounding media. At days 14 and 21, this amount is more pronounced with an increase 
in bFGF at day 14 relative to day 0 (p≤0.05) and BM (p≤0.05), and day 21 relative to day 
0 (p≤0.05) and BM (p≤0.05). * Indicates statistical significance. Data is presented as 
bFGF concentration (µg/mL) ± SEM. 
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5.8. Blocking bFGF or CD44 on Whole Population MDA-MB-231 Cells Does 
Not Decrease Cellular Growth in the PuMA
We next wanted to determine the influence of bFGF on cellular growth and 
proliferation in the native lung microenvironment in the context of the PuMA. Using 
the highly metastatic  MDA-MB-231 whole  cell  population,  cells  were either  pre-
incubated with an anti-CD44 antibody in HBSS or in HBSS alone prior to injection. 
Cells were then delivered to female nude mouse lungs by tail vein injection (5 x 105 
cells/mouse, n=3 mice). Lungs seeded with cells pre-incubated with an anti-CD44 
antibody were  infused  and  excised  as  per  the  PuMA protocol  (Figure  7).  Lungs 
seeded with cells  pre-incubated with HBSS only were either  infused with normal 
agarose/media  1  solution  or  agarose/media  1  solution  plus  a  neutralizing  bFGF 
antibody  before  following  the  remainder  of  the  PuMA protocol.  Sections  were 
cultured in serum-free conditions and imaged at days 0, 7, 14 and 21 using confocal 
microscopy to evaluate cellular growth and progression.  Following imaging, there 
was a slight decrease in cellular growth and progression for bFGF blocked or CD44 
blocked groups compared to normal seeded lungs by day 21 (Figure 15A,B,C). There 
was a trend towards decrease in overall growth in the presence of a neutralizing bFGF 
antibody or in cells pre-incubated with an anti-CD44 antibody at days 7, 14, and 21, 
although  this  did  not  reach  statistical  significance  (p>0.05)  (Figure  15D). 
Significance between experimental groups at a given time point was determined by 
two-way ANOVA with a Sidak’s post test. Error bars represent ± SEM.  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Figure 15. Blocking bFGF and CD44 has no effect on growth reduction of whole 
population MDA-MB-231 cells in the PuMA. To determine the influence of bFGF on 
breast cancer growth in the context of the PuMA, both bFGF and one of its receptors on 
breast cancer cells, CD44, were blocked. For bFGF blocking, cells were injected as per 
the PuMA assay with the exception that lungs were infused with a neutralizing bFGF 
antibody within the agarose/lung media 1 solution. For CD44 blocking, cells were pre-
incubated with an anti-CD44 antibody prior to injection. The PuMA was carried out as 
described above. (A,B,C) Representative images for normal seeded lungs, normal seeded 
lungs infused with a neutralizing bFGF antibody and seeded lungs pre-incubated with an 
anti-CD44 antibody. Scale bars represent 100 µm. A mean normalized fluorescent area 
(µm2) per image was measured and averaged for each time point for each experimental 
group. (D) A trend towards decrease in overall growth is seen for cells grown in the 
presence of a neutralizing bFGF antibody or cells pre-incubated with an anti-CD44 
antibody at days 7, 14, and 21, however this did not reach statistical significance 
(p>0.05). Error bars represent ± SEM. 
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6. DISCUSSION
 Breast cancer incidence has remained relatively constant over the past 10-15 
years, with a general decline in the number of individuals succumbing to this type of 
cancer. Despite the decreasing deaths rate associated with breast cancer, it still 
represents the most frequently diagnosed cancer in women and the second leading 
cause of all cancer related deaths in women in North America [2, 3, 106].  
Research  advances  in  the  field  of  cancer  have  generated  a  wealth  of 
knowledge concerning how cancer initially develops and the potential targets worth 
exploiting. However, as we gain a greater understanding of the complexities of both 
the tumour and the tumour microenvironment, we are beginning to appreciate the vast 
heterogeneity that exists within the tumour population. This in part has led to many 
failed  therapeutics  and  treatments  in  the  metastatic  setting,  increasing  the  risk  of 
relapse and cancer recurrence in patients. It is therefore paramount that we put forth 
efforts to better understand the mechanisms that determine why tumours spread in the 
patterns they do and ultimately how this metastatic process occurs once single cells 
reach secondary organs.
The lung is one of the most frequent sites of metastasis associated with breast 
cancer, as a result of its large surface area and dense capillary network that make it 
ideal for tumour cell stasis during circulation. Much work has been done investigating 
the  genetic  signatures  of  breast  cancer  cells  associated  with  specific  patterns  of 
metastatic  spread,  specifically  to  the  lung.  This  work,  largely  pioneered  by  Joan 
Massagué and related  groups,  has  increased our  understanding of  the  the  genetic 
signatures that certain tumour cells acquire for lung-specific tropism [56]. However, 
genetics alone do not account for patterns of metastatic spread, and we are beginning 
to understand the profound influence of specific organ microenvironments and their 
relationship  with  tumour  development.  It  has  remained  a  technical  challenge  to 
understand the implications of both the soluble and insoluble microenvironments in 
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secondary organs, particularly in the lung as they relate to metastatic progression. 
Therefore,  this  study  utilized  a  relatively  new  and  innovative  model  system  for 
studying  the  influence  of  the  lung  microenvironment  on  breast  cancer  cells.  The 
pulmonary metastasis assay (PuMA) has allowed us to investigate the effect of both 
the soluble and insoluble lung microenvironments on the behaviour of breast cancer 
cells,  specifically  stem-like  ALDHhiCD44+  cells,  from  the  single  cell  stage  to 
multicellular colonies. This model will ultimately help elucidate how breast cancer 
cells interact with the lung during metastatic progression and allow us to develop 
methods of exploiting this microenvironment to limit growth and progression, with 
hopes of eventual translation to the clinic.
We set forth to test the hypothesis that stem-like ALDHhiCD44+ breast cancer 
cells demonstrate increased growth and progression from a single cell stage within 
the  PuMA compared  to  their  non  stem-like  ALDHloCD44-  counterpart.  To  our 
knowledge, we are the first group to utilize this innovate ex vivo model system for 
tracking the metastatic behaviour of stem-like breast cancer cells within the lung in 
real time. 
6.1. Summary of Experimental Findings 
1. An innovative ex vivo pulmonary metastasis assay (PuMA) was established in our 
laboratory and demonstrated to maintain mouse lung viability and relevant lung 
architecture in culture for 21 days, as reported by previous studies [93, 102].
2. Whole population MDA-MB-468, SUM149 and MDA-MB-231 breast cancer cell 
lines  differentially  progressed within  the  PuMA with  highly  metastatic  MDA-
MB-231 cells actively proliferating and showing the greatest degree of growth.
3. ALDHhiCD44+  breast  cancer  cells  isolated  from  both  SUM149  and  MDA-
MB-231 human cell lines showed increased growth and progression from single 
cells in the PuMA, relative to the non stem-like ALDHloCD44- population.
4. ALDHhiCD44+  breast  cancer  cells  isolated  from  both  SUM149  and  MDA-
MB-231  cell  lines  progressed  from  single  cells  (≤50  μm  in  diameter)  to 
micrometastatic (100-400 μm) colonies within the PuMA, with MDA-MB-231 
cells also progressing even further to macrometastatic colonies (>400 μm).
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5. Basic fibroblast growth factor (bFGF) was shown to be present in both lung-CM 
and the intact lung microenvironment in the PuMA.
6. Depletion of bFGF from mouse lung-CM significantly reduced the proliferation 
of both SUM149 and MDA-MB-231 cells in vitro, but had no effect on cellular 
migration.
7. Blocking of either bFGF or its receptor CD44 did not significantly reduce cellular 
growth and progression in the context of the PuMA.
6.2. Advantages of the PuMA as a Model for Metastasis 
 Over 20 years ago, Siminski and colleagues successfully established a novel ex 
vivo model system for studying the pathogenesis of lung injury. They required a 
model system that accurately mimicked the in vivo environment of the lung, while at 
the same time being simple and practical. With their model, they were able to 
maintain normal pulmonary architecture and viability for up to 9 weeks in culture, in 
serum free conditions [102]. It wasn’t until recently that this protocol was adapted to 
model cancer metastasis in a secondary environment.  
To  accurately  study  the  biology  of  metastasis,  an  optimal  assay  would 
conveniently  recapitulate  the  complexity  of  the  cellular  and  non-cellular 
microenvironment,  while  at  the same time allowing a  “glass  window” to observe 
metastatic progression. As a starting point, in vitro approaches are often employed. 
These  techniques  are  rarely  sufficient  in  modelling  the  complex  interactions  that 
occur between tumour cells and the host environment, both cellular and non-cellular. 
To complement this, in vivo models, most often in mice, are required. However, these 
models too often examine only the end-point of metastatic outcome (whether or not 
secondary tumours have been established) and the time to late-stage metastatic events 
[93, 107]. In order to bridge the gap between these traditional models of studying 
metastasis,  Mendoza  et  al.  adapted  the  ex  vivo  model  system  first  put  forth  by 
Siminski some 20 years earlier. Their model, which they described as a pulmonary 
metastasis assay (PuMA), was able to effectively discriminate between both weakly 
and highly metastatic human and murine cancer cell lines that accurately modelled 
their behaviour previously observed in vivo [93]. Their study therefore introduced a 
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powerful  tool  for  understanding  the  progression  of  metastasis  in  a  secondary 
environment.
We therefore utilized this innovative assay in order to better understand breast 
cancer behaviour and metastatic progression in the context  of  the lung,  a process 
often associated with high rates of mortality. We were able to effectively demonstrate 
that normal unseeded lung sections maintained in culture remained relatively healthy 
and intact throughout the 21 day period. Important to this assay was that the gross 
pulmonary architecture remained intact with no visible areas of collapse or loss of 
structure with the presence of  structural  components  (muscle tissue and collagen) 
identified  at  each  time  point.  Infusion  of  a  0.6%  agarose  solution  prior  to  the 
extraction of lungs was key to maintaining airways in an expanded state throughout 
the duration of the assay. Other groups have demonstrated that without the inclusion 
of agarose, lung architecture is almost completely lost within the first 24 hours in 
culture  [93].  In  addition  to  intact  pulmonary  architecture,  we  have  shown  that 
cellularity also remains in the lung during the assay. Using H&E staining, there is 
evidence of cellular nuclei present throughout the lung at each time point of the assay. 
More specifically, we were able to identify and distinguish between type I and type II 
pneumocytes  at  the  level  of  the  alveoli  at  each  time  point  throughout  the  assay. 
Although there was an overall qualitative loss of cellularity within the lung at days 14 
and 21 compared to earlier time points as expected [93], the lung microarchitecture 
remained remarkably unchanged.
We next tested three breast cancer cell lines, each with varying degrees of 
metastatic  behaviour  in  vivo:  very  weakly  metastatic  MDA-MB-468,  weakly 
metastatic SUM149 and highly aggressive MDA-MB-231. Both MDA-MB-468 and 
MDA-MB-231 cells were originally derived from the pleural effusions of patients 
with breast cancer. In terms of molecular subtype, these cell lines are both classified 
as triple negative (TN) and have a EGFR+/TGF+/ER-/PR-/HER2- phenotype [108, 
109]. SUM149 cells were isolated from a patient with primary inflammatory breast 
cancer.  These  cells  bear  a  EGFR+/HER2,3+/HER4-/ER-/PR- phenotype  [110].  Cell 
lines  demonstrated  growth  patterns  that  accurately  paralleled  their  metastatic 
behaviours in vivo.  Previous studies have established the behaviours of  these cell 
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lines  in  vivo  and  although  MDA-MB-468  whole  population  and  stem-like  cells 
isolated based on an ALDHhiCD44+CD133+ phenotype have produced lung tumours 
in mice injected by tail-vein, their mean metastatic burden (percentage of total lung) 
was  quite  low  (<1%),  indicating  an  inability  of  these  cells  to  progress  to 
macrometastatic  colonies.  Conversely,  whole  population  and ALDHhiCD44+CD24- 
stem-like MDA-MB-231 cells have produced a much higher metastatic burden within 
the lung (>15%) and consistently produce macrometastases [52, 67]. Therefore, it’s 
not surprising the MDA-MB-468 cell line produced the smallest degree of growth 
within the PuMA relative to the more aggressive SUM149 and MDA-MB-231 cell 
lines. Results of this study therefore validate this model as an effective surrogate for 
studying in vivo breast cancer metastasis. The PuMA provides an advantage over both 
in  vitro  and  in  vivo  techniques  for  studying  metastasis.  Cells  often  behave  quite 
differently when cultured on plastic compared to a native environment. For example, 
in  one  particular  study,  lung  cancer  cells  grown  in  2D  tissue  culture  expressed 
significantly lower levels of MMP-1, 9, 10 and no expression of MMP-9 compared to 
the same cells grown in a native 3D lung matrix maintained in a bioreactor [111]. 
Therefore,  the  PuMA provides  a  more  biologically  relevant  way for  studying the 
behaviour of breast cancer within a secondary environment, something not always 
feasible with in vitro  studies. Furthermore, the PuMA allows for the possibility of 
real-time assessment of metastatic progression at multiple time points using a single 
mouse lung. To accomplish this in vivo would require a vast number of mice as well 
as investigator time. In addition, studying metastatic progression from the single cell 
level is rarely achievable in vivo due to resolution limitations with current imaging 
techniques. Therefore, in this regard, the ex vivo PuMA provides a more efficient and 
cost effective strategy for evaluating metastatic progression in a native environment 
and allows for studying the behaviour of breast cancer from a single cell stage once 
cells have immediately reached the lung.
6.3. ALDHhiCD44+ Breast Cancer Cells Drive Metastatic Progression Within 
the Lung Microenvironment
 Evidence within the literature suggests that only a small subset of cells are able 
to successfully navigate the metastatic cascade to eventually initiate and form 
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secondary metastases. It has therefore been postulated that cancer stem cells (CSC) or 
stem-like cancer cells represent the subset of tumour cells responsible for metastatic 
disease [61, 112]. In breast cancer, the population of CSCs are traditionally isolated 
based on both surface markers (CD44+CD24-) and functional activity (ALDHhi). The 
utilization of both functional activity in addition to surface markers increases the 
validity of isolation due to the inherent heterogeneity of tumour cell surface marker 
expression as a result of genetic instability [67, 113-115]. In this study, we isolated 
stem-like breast cancer cell populations using a two marker strategy. Therefore, we 
isolated stem-like cells using ALDH as a primary sort criteria and CD44 expression 
as secondary sort criteria. Previous studies have shown similar functional metastatic 
capabilities between cells isolated using an ALDHhiCD44+ approach versus cells 
isolated using ALDHhiCD44+CD24- [65, 67], and we therefore did not include CD24 
in our cell sorting criteria. Therefore, we are confident that the cells isolated from 
both cell lines used in this study represent the most aggressive and metastatic 
population.  
 Our specific interests relate to understanding the contribution of ALDHhiCD44+ 
breast cancer cells during the process of metastasis, and how the lung 
microenvironment ultimately interacts with these cells to promote metastases 
formation once these cells immediately reach the lung. Although there is a wealth of 
knowledge concerning the existence of stem-like cancer cells in primary tumours, 
much less is known regarding the functional and mechanistic implications of these 
cells in mediating metastasis. Using the PuMA, we have evaluated the growth and 
progression patterns for both stem-like and non stem-like breast cancer cells within 
the native lung microenvironment. We have observed that breast cancer cell 
populations isolated based on an ALDHhiCD44+ phenotype demonstrate increased 
growth over the course of 21 days compared to ALDHloCD44- cells. Moreover, stem-
like ALDHhiCD44+ progressed within the PuMA from single cells once delivered to 
the lungs, to micrometastases (SUM149, MDA-MB-231) to macrometastases (MDA-
MB-231), whereas the majority of non stem-like cells in both cell lines remained 
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predominantly as single cells, showing very little progression to the micrometastases 
stage, if any. Together these results indicate that breast cancer cells, specifically the 
stem-like ALDHhiCD44+ population, are responsible for metastatic progression within 
the lung. Differences in growth are not a result of a discrepancy in cellular delivery, 
since a similar number of both ALDHhiCD44+ and ALDHloCD44- cells are able to 
reach the lungs initially at day 0. Therefore, it is specifically the stem-like population 
that is able to interact with the native lung microarchitecture to successfully establish 
secondary tumour populations, whereas the majority of non stem-like cells remain as 
single cells and fail to progress past the micrometastases stage. Importantly, the 
PuMA assay has allowed us to dissect out the role of the lung microenvironment in 
mediating the 2 most significant rate-limiting steps in metastasis (and those we 
hypothesize to be facilitated by stem-like cells): the transition from single cells to 
micrometastases, and from micrometastases to macrometastases [116, 117]. This is 
very difficult to do in real-time using in vivo models, since most imaging technologies 
do not have this degree of sensitivity, particularly in the lung. 
6.4. The Complexity of the Lung Microenvironment
The microenvironment of organs is comprised of normal parenchymal cells, 
stromal cells and insoluble elements including the ECM and ECM-related factors as 
well  as  soluble  factors  [118].  We  are  beginning  to  appreciate  how certain  organ 
microenvironments  can  influence  the  biology  of  tumour  growth  and  survival,  a 
concept that’s relatively new in the field of metastasis. As stated by Fidler in a review 
of the organ microenvironment and metastasis, the extent of tumour cell proliferation, 
invasion,  angiogenesis  and  survival  are  in  part  determined  by  the  specific  organ 
microenvironment [48]. 
The lung microenvironment is no exception to this complexity. The lung is 
composed of a dense vascular network, surrounded by over 60 different cellular types 
including cells with sensory, secretory, mechanical and transport functions [119], each 
with distinct expression patterns for soluble factors. Moreover, the insoluble ECM 
and  ECM-related  components  of  the  lung  function  as  a  scaffold  for  these  cells. 
Therefore, there are many potential sources in the lung microenvironment that may 
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contribute to the metastatic behaviour of breast cancer cells once they reach the lung. 
Together,  these  factors  probably  do  not  influence  the  behaviour  of  breast  cancer 
exclusively but  rather,  many of  these components  likely act  together  to  drive the 
process of breast cancer metastasis within the lung. Previous work done in our lab has 
focused primarily on the soluble component of the lung microenvironment and thus 
was used as a potential target in this study.
Work done by Jenny Chu has identified over 70 soluble factors within the lung 
microenvironement that may be contributing to the growth and metastatic behaviour 
of breast cancer once they reach the lung [52]. This work predominantly concentrated 
on the soluble lung microenvironment and its role as a chemoattractant for breast 
cancer cells. Her work demonstrated that soluble factors within lung-CM including 
the CD44 ligands osteopontin (OPN) and L-selectin (SELP) mediated breast cancer 
cell migration in vitro [52]. Although her work led to a greater understanding of the 
contribution of  the soluble  lung microenvironment  to  the “getting there” stage of 
breast cancer metastasis, much less has been explored in terms of the “growing there” 
portion  of  breast  cancer  metastatic  progression.  One  of  the  proteins  previously 
identified within lung-CM and of particular interest to us was bFGF.
6.5. bFGF in the Lung Microenvironment
We were especially interested in the role of soluble bFGF and its influence on 
breast cancer cell metastatic behaviour and progression within the lung, particularly 
in the context of the ex vivo PuMA. bFGF is well known for its potent mitogenic 
effects, with many of its pro-proliferative activity linked to promoting growth and 
proliferation  in  primary  precursor  cells  [120].  Coupled  with  the  fact  that  this 
particular protein is involved in the maintenance of self-renewal in stem cells and 
often  found  in  media  for  culturing  stem cells  [121],  we  sought  to  determine  its 
influence on breast cancer cell behaviour both in vitro and in the PuMA. Therefore, 
bFGF  represented  an  appropriate  target  worth  exploring  within  the  lung 
microenvironment especially since murine and human bFGF share a 97% amino acid 
sequence identity (UniProtKB/Swiss-Prot-P09038).
Using our previously described ex vivo murine model system for generating 
organ conditioned media [52], we were able to show that bFGF present in mouse 
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lung-CM increased the proliferation of both SUM149 and MDA-MB-231 whole cell 
populations  as  assessed  by  BrdU  incorporation.  Moreover,  this  increase  in 
proliferative behaviour was abrogated following the immunodepletion of bFGF from 
lung-CM  and  could  be  rescued  by  re-introducing  recombinant  bFGF  to 
immunodepleted  media.  Interestingly,  we  observed  a  lack  of  migratory  responses 
towards bFGF using Transwell migration assays which indicated that this protein was 
more important for promoting proliferation versus migration of breast cancer cells. 
Taken  together,  these  results  suggest  that  bFGF may  play  more  of  a  role  in  the 
“growing there” versus “getting there” stage of breast cancer metastasis. Although 
bFGF has previously been characterized as a chemoattractant, most of these studies 
have been in the context of evaluating the process of angiogenesis, using endothelial 
cell lines, not breast cancer cells [122]. 
Following  in  vitro  experiments  suggesting  the  role  of  bFGF in  promoting 
proliferation of breast cancer cells, we aimed to target this protein in the PuMA to 
determine if we could interfere with breast cancer cell growth and progression. We 
chose to evaluate the response of highly metastatic MDA-MB-231 whole population 
cells due to their prominent growth observed in the PuMA compared to the other cell 
lines (MDA-MB-468 and SUM149). We first demonstrated the presence of bFGF in 
the  intact  lung  used  within  the  PuMA.  Immunohistochemical  staining  for  bFGF 
revealed  a  diffuse  pattern  of  staining throughout  the  lung,  with  a  high degree  of 
positive staining surrounding vasculature. This pattern of staining was expected as 
bFGF  is  normally  expressed  ubiquitously  and  present  in  high  amounts  in  the 
basement membranes and ECM of blood vessels [123]. We were also able to show 
that bFGF was present within the Gelfoam® that lung sections were grown on during 
the PuMA. Over the course of 21 days, there was an increase in the amount of bFGF 
detected at later time points, compared to earlier ones. This increase coincided with 
the length of time that lung sections spent on the Gelfoam® throughout the assay. 
Despite the changing of media every other day, an increase in concentration was still 
observed suggesting that bFGF was continuously secreted by the sections of lung 
grown on Gelfoam® and that  secreted bFGF remained bound or stuck within the 
network of the Gelfoam®.
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To determine the effect of bFGF in the ex vivo PuMA, we utilized antibody-
mediated blocking of  both mouse bFGF produced in  the  lung and CD44,  a  non-
canonical  bFGF  receptor  present  on  breast  cancer  cells.  Although  no  significant 
reduction in breast cancer growth in the lung was observed, data indicated a general 
trend towards a reduction in growth of MDA-MB-231 cells. Due to the difficulty of 
blocking these proteins continuously over the course of 21 days, the negative results 
may be due to technical challenges rather than a lack of biological response. First, 
lung sections, although thin (~1 mm), still represent a significant area for penetration 
of antibody during the assay. Therefore, simply adding fresh antibody throughout the 
assay would not increase the exposure between antibody and tumour cells. Therefore, 
we  opted  to  instead  perfuse  the  lung  with  a  mouse-specific  neutralizing  bFGF 
antibody prior to the removal of lungs from mice and pre-incubated cells with an anti-
CD44 antibody prior  to  tail-vein  injection.  For  bFGF blocking in  the  PuMA, we 
chose to use a concentration of antibody equal to the amount needed to successfully 
deplete lung-CM. Therefore, another potential source of negative response may be 
due to an ineffective concentration of neutralizing bFGF antibody initially used when 
perfusing  the  lung,  or  a  diminishing  biochemical  activity  of  bFGF  antibody 
throughout the assay. Unfortunately, there is very little data within the literature to 
suggest an appropriate starting point for antibody-mediated blocking using the PuMA 
since this is a relatively new model.  Work that has been done regarding targeting 
within  the  PuMA  is  primarily  focused  on  testing  chemotherapeutics  and  not 
antibodies  [93].  For  CD44 blocking,  cells  were  pre-incubated  with  an  anti-CD44 
antibody prior to injection. Therefore, a negative reduction in growth associated with 
blocked CD44 may indicate the antibody does not remain bound during the initial 
seeding to the lung or a diminishing biological activity throughout the assay. Another 
possible explanation is that breast cancer cells are able to compensate for decreased 
CD44 receptor activity in relation to bFGF by using its canonical receptor (FGFR1), 
normally  expressed by MDA-MB-231 cells  [85]  or  other  receptors  involved with 
fine-tuning  bFGF  signalling  (integrin  vβ3,  heparin,  thrombospondin,  fibrinogen, 
PDGF) [83]. Ultimately, more work needs to be done with regards to optimization of 
antibody-mediated blocking techniques within the PuMA before we can confidently 
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rule  out  bFGF as  a  potential  target  within the native lung microenvironment  that 
could reduce the metastatic behaviour of breast cancer cells.
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7. POSSIBLE LIMITATIONS OF THE STUDY
Findings  and  subsequent  conclusions  made  in  this  study  are  based  upon 
certain assumptions, particularly concerning features of the presented ex vivo models. 
The  PuMA  represents  an  innovative  model  system  for  assessing  growth  and 
progression of cancer cells in real time within a native lung environment. While this 
model  illustrates  a  promising approach for  studying breast  cancer  metastasis  in  a 
secondary environment, like most models, it is not without its limitations. 
The first assumption is that breast cancer cell growth and progression in the 
PuMA is not influenced by the immune system. This study utilized athymic Nude-
Foxn1nu mice which have an inhibited immune capacity due to a reduced number of 
mature T-cells. Because of this, they are unable to mount adaptive immune responses 
and are therefore ideal for studying the growth of solid tumours derived from humans 
[124].  Nude  mice  were  also  chosen  to  compare  current  and  future  results  with 
previous in vivo findings using this mouse strain. In addition, in context of the PuMA, 
due to the excision of the lungs from nude mice and subsequent slicing of the lung, 
there is no active immune system regardless. While in theory, the advantage of the 
PuMA is that it accurately represents the pulmonary architecture that breast cancer 
cells  would  encounter  physiologically,  it  still  does  not  take  into  account  the 
contribution  and  possible  interaction  of  the  immune  system  during 
immunosurveillance of tumour cells.
The second assumption is that murine secreted factors and insoluble matrix 
components  interact  with  human  cancer  cells  both  in  the  PuMA and  lung-CM. 
Traditionally, murine models are utilized because they are small, easy to handle and 
have  consistent  disease  manifestations.  More  importantly,  mice  have  over  a  95% 
similarity to human genetics, with many genes showing high degrees of conservation 
between the two species.  Despite the significant evolutionary genetic conservation 
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between  mice  and  humans,  certain  ligand-receptor  interactions  may  remain 
incompatible between the two species. However, many secreted murine factors are 
still able to stimulate cellular responses in human cells [125]. Ethically speaking, the 
collection of human lungs in lieu of murine lungs presents a challenge and is not 
feasible, thus the murine model system was both practical and essential.
The third assumption in terms of the ex vivo lung-CM model system is that 
lung-derived soluble factors are adequate for inducing changes in cellular behaviour, 
particularly migration and proliferation. In reality, the metastatic niche is composed 
of insoluble factors, ECM components and various cell types in addition to soluble 
factors.  All  of  these  factors  can  potentially  contribute  to  tumour  cell  behaviour. 
Although, changes in cellular proliferation were seen in this study, results would have 
been strengthened with the addition of the ECM or ECM-related components to the 
assay outlined above.
Finally, as with most basic science cancer research, these studies relied on 
immortalized human cell lines rather than primary human breast cancer cells. While 
immortalized cells used in this study originated from primary patient samples, they 
have  undergone significant  mutations  to  become immortal.  In  addition,  there  still 
represents  the potential  for  these cell  lines to acquire additional  mutations due to 
failures  in  DNA repair.  Although  immortalized  cell  lines  are  easy  to  obtain  and 
maintain in culture, they still may not accurately represent the true behaviour present 
with primary patient-derived breast cancer cells.
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8. FUTURE DIRECTIONS
As mentioned previously, the occurrence of lung metastases in breast cancer 
patients  is  often  associated  with  high  rates  of  mortality.  This  highlights  the 
importance  of  understanding  the  contribution  of  the  lung  microenvironment  as  a 
whole  in  mediating  lung related  metastatic  spread.  Therefore,  elucidating  specific 
factors or signals involved in promoting lung specific tropism in breast cancer should 
remain a strong focus. 
The  molecular  basis  for  organ-specific  metastasis  has  started  to  gain 
significant attention amongst the scientific community, especially as we continue to 
discover the disparity between the behaviour of primary tumour cells and those in the 
metastatic setting. Traditionally, metastasis-related research tends to focus more on 
the end point, e.g. after a clinically detectable tumour has developed. This approach 
often  overlooks  the  importance  of  the  initial  steps  of  tumour  establishment  and 
subsequent metastatic progression. One of the main advantages of the PuMA is that it 
shifts the focus from the end point of metastatic development by also incorporating 
the  initial  stages  of  metastatic  progression.  Therefore,  future  work  should  centre 
around determining aspects of the lung microenvironment responsible for promoting 
successful  micrometastases  development.  This  study  in  particular  focuses  on  one 
soluble factor specifically, bFGF. Methods in addition to antibody-mediated targeting 
of bFGF, such as small molecule inhibitors should be utilized to determine the full 
extent of bFGF influence on breast cancer cell behaviour. For example, the chemical 
SSR128129E has been shown to effectively inhibit bFGF signalling by binding to the 
extracellular domain of FGFR receptors [126-128]. Additionally, selective FGFR1/3 
small  molecule  inhibitors  including  PD173074  [129-131],  and  FGFR1  inhibitors 
including  PD161570  [132,  133] also  exist  and  provide  another  possible  route  of 
inhibition. These small molecule inhibitors have been used both in vitro and in vivo 
and  show promise  for  decreasing  the  growth  of  certain  cancers.  However,  these 
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molecular inhibitors have not been used in the context of either breast cancer or breast 
cancer metastasis, and thus provide encouraging methods for inhibiting bFGF within 
the PuMA. To further complement blocking of bFGF within the PuMA, future work 
in assessing bFGF could be better suited using a systemic bFGF knockout mouse 
model.  The  Fgf2tm3Doe/Fgf2tm3Doe  mouse  model  provides  a  unique  approach  for 
evaluating the behaviour of breast cancer cells in an environment devoid of bFGF. 
These mice develop and age normally with a normal lifespan and exhibit  regular 
organ architecture [134]. Therefore, these mice could be used in the context of the 
PuMA outlined above using syngeneic mouse breast cancer cell lines. Comparisons to 
mice with normal bFGF expression or to bFGF knockout mice with re-introduced 
bFGF (added to the infused agarose/media 1 solution) could be used to fully gauge 
the effect of bFGF on breast cancer cell behaviour in the lung.
However, many other soluble factors in addition to bFGF may be contributing 
to the metastatic behaviour of breast cancer within the lung. Therefore, the PuMA can 
be used as a high throughput screening tool in the future for inhibiting other soluble 
factors in the lung microenvironment that may have a contribution to the metastatic 
progression of breast cancer. The PuMA not only represents an innovative method for 
targeting specific soluble  factors  within  the  lung but  also  provides  an avenue for 
screening potential therapeutics. One disadvantage of traditional in vivo screening of 
therapeutics is the sheer number of animals needed and the associated cost. With the 
PuMA, many sections of lung from the same mouse/animal can be used as a much 
cheaper high throughput technique for determining proper drug concentrations and 
dosing regimes with  many different  therapeutics  at  once.  This  also  has  an  added 
advantage  over  traditional  cell  culture  based  screening  as  cells  often  behave 
differently within a native 3D environment opposed to on 2D tissue culture plastic. 
Therefore, the PuMA provides not only a unique ex vivo method for studying the 
behaviour of cancer cells in a native environment but also brings the ability to screen 
many  different  targeted  and  non-targeted  therapeutics  in  a  biologically  relevant 
setting.
Finally,  another  advantage  of  the  PuMA is  that  it  provides  an  appropriate 
native 3D architecture onto which breast cancer cells interact. Since the PuMA is able 
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to maintain lung viability throughout the duration of the assay, the architecture on 
which breast  cancer cells  interact  include both the soluble and the insoluble lung 
microenvironment.  Although this  study focuses on specific soluble factors  present 
within  the  lung  microenvironment  that  may  be  contributing  to  breast  cancer  cell 
growth  and  behaviour,  we  cannot  discount  the  importance  of  the  insoluble 
component, including the ECM. In fact, it has been shown that the ECM is a crucial 
component  of  the  metastatic  niche  and  plays  an  important  role  in  mediating  the 
metastatic progression of cancer [135]. A future goal of ours in collaboration with Dr. 
Lauren Flynn (Western University) is the development of a decellularization protocol 
to  effectively  eliminate  the  cellular  presence  within  the  lung,  leaving  only  the 
insoluble ECM scaffold. We are particularly interested in the growth patterns of both 
whole population and stem-like ALDHhiCD44+ breast cancer cells in the native lung 
versus a decellularized lung containing only a 3D matrix scaffold. In order to pursue 
this, we are looking at assessing breast cancer behaviour in a modified version of the 
PuMA. Traditionally in the PuMA, cells are seeded to the lung via the vasculature 
(tail-vein injection). However, in the context of comparing between native lung and a 
decellularized lung, there is no functional vasculature to utilize in seeding the lung. 
Therefore,  cells  should  instead  be  seeded  to  the  lung  in  both  the  native  and 
decellularized  lung  by  means  of  the  trachea.  Although  this  does  not  accurately 
recapitulate  what  occurs  physiologically,  it  represents  a  more  consistent  way  to 
compare  between  lung  conditions.  The  seeding  of  decellularized  lungs  with  lung 
cancer cells via the trachea has been accomplished successfully by other groups and 
we are confident this approach will provide an accurate avenue for comparing growth 
patterns between lung conditions [89]. This work is currently underway.
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9. FINAL CONCLUSIONS
  
 Since the majority of deaths associated with breast cancer can be attributed to 
metastasis, and more specifically to breast cancer that has spread to the lung, we 
sought to determine the influence of the native lung microenvironment on the 
behaviour of breast cancer cells. There are often many limitations associated with 
studying the progression of metastasis in vitro. This thesis made use of an innovative 
ex vivo pulmonary metastasis (PuMA) model to test the hypothesis that stem-like 
ALDHhiCD44+ breast cancer cells demonstrate increased growth and progression 
from a single cell stage within the native lung in relation to their non stem-like 
ALDHloCD44- counterparts. Although the PuMA has been used to study the 
behavioural differences between weakly and highly metastatic osteosarcoma cells 
within the lung, to our knowledge, we are the first group to utilize this unique ex vivo 
assay to model breast cancer metastasis within the lung, with a specific interest in the 
progression differences between stem-like and non stem-like cells. This study not 
only answers questions that we initially posed, but has provoked many additional 
questions for the future. Therefore, this study represents a novel stepping stone for the 
development of future research questions and studies. 
 Overall, this study supports evidence from both our lab and the literature 
suggesting that small subset of tumour cells, which bear similar characteristics to 
normal stem-cells, are ultimately responsible for the growth and progression of 
secondary tumours after they have spread beyond the initial site of origin. We have 
taken a unique approach in that we have tracked the progression of stem-like breast 
cancer cell growth from the single cell stage in real time once they’ve immediately 
reached the lung to study the initial steps of metastatic progression. This lung-specific 
model for breast cancer metastasis has the potential to uncover key processes during 
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the initial stages of lung metastasis and offers a valuable tool for future research 
geared towards exploring and targeting certain aspects of the lung microenvironment, 
including both the soluble and insoluble components to limit the extent of lung-
related spread in breast cancer patients.  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